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Abstract 
 
Background: The immune microenvironment in the colon has the potential to generate an 
anti-tumour response, but this response is ineffective when cancer develops. We know that 
the predominant immune cells present in colorectal cancer (CRC) are CD4+ T-
lymphocytes.  Subtypes of CD4+ T-cells can either enhance an immune response, by a T-
Helper type-1 response (CD4+ THC) or dampen down the response (CD4+ T-regulatory 
cells).  The hypotheses are that (i) the CD4+ component of T-cells in colorectal cancer is 
not homogenous, but made up of various different functional subtypes, such as T-helper 
and T-regulatory cells, (ii) that CD4+ cells in CRC are heterogeneous in their expression 
of cell surface homing markers, and (iii) the presence of certain cell surface markers can 
identify cells with a typical functional response.   
 
We know that in peripheral tissues dendritic cells first display antigen to CD4+ T-cells in 
local lymph nodes. The experimental set included analysis of paired tumour and local 
lymph node lymphocytes, along with paired peripheral blood lymphocytes for comparison. 
Assays that are widely used to assess phenotype and function of peripheral blood 
lymphocytes (PBL) were validated for their use with tumour infiltrating lymphocytes 
(TIL) and local lymph node lymphocytes (LNL).   
 
Methods: Blood samples were obtained from 38 patients, and tumour from 35 and lymph 
node biopsies were harvested from 26 of these patients.  PBL were isolated by ficoll 
separation. TIL and LNL were extracted using mechanical disaggregation.  Small groups 
of experiments were performed as the lymphocyte yield per case would not allow all 
assays to be performed on samples from each patient. For each patient it was possible to 
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use lymphocytes to perform both a phenotypic analysis (with flow cytometry) and a 
functional analysis (e.g. ELISA). The first series of experiments assessed the presence of 
CD4+CD25+ cells as a putative marker for regulatory T-cells, and functional analysis 
using ELISA was validated. For this, PBL, TIL and LNL were stimulated and the release 
of several inflammatory cytokines measured with ELISA.  The second series of 
experiments involved staining CD4+ cells with a panel of 18 T-cell homing markers to 
identify any markers that appeared to be up-regulated in TIL from CRC.  As there was 
little data in the literature regarding homing marker expression in normal mucosa, mucosal 
infiltrating lymphocytes were also harvested from these patients. Based on the homing cell 
surface markers identified, lymphocyte isolates were separated using Flow Assisted Cell 
Sorting or MACS separation, and the functional ability of these subpopulations assessed 
using ELISA. 
 
Results:  TIL from CRC display up-regulation of homing factors CXCR6, CCR5, and 
CCR6 (p=0.0001, 0.01782 and 0.5346 respectively).  The most dramatic (and only 
statistically significant) increase was seen with CXCR6. Stimulated CD4+CXCR6+TIL 
produced interferon-gamma, a cytokine involved in anti-tumour responses. We have also 
confirmed the presence of a population of inhibitory FoxP3+ and CD4+CD25+ T-
regulatory cells.   
 
Conclusion: In addition to identifying subpopulations of THC within CRC, we have 
described methods of standardising the techniques used so that they may be used to 
monitor the effect of future vaccine trials on the tumour immune microenvironment. 
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1 Introduction 
 
 
Current understanding of the T-cell response in colorectal cancer (CRC) is limited. The 
rationale of this study is that understanding more fully the specific functions of CD4+ T-
cells present in CRC is important for enhancing our understanding of the cellular 
interactions that contribute to cancer development, and it will also will allow us to assess 
the effect on the immune system of new treatments such as immunotherapy, that to date 
have failed to improve survival from this disease. The following sections outline current 
understanding of the pathological development of colorectal cancer, and its current 
treatment strategies. 
 
 
1.1 The Diversity of Colorectal Cancer 
 
Every colorectal cancer is unique. Its development depends on several factors all of which 
show variability from one tumour to the next; a series of genetic changes, epigenetic 
phenomena, altered surrounding stroma, angiogenesis and alteration of the local immune 
response. It is the cell: cell interactions between tumour cells and also the interactions with 
stroma and immune cells that determines how a cancer grows and behaves. Understanding 
this diversity in the pathological process is key when considering how we can improve the 
analysis, staging and subsequent treatment of colorectal cancer. 
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1.1.1 Genetic Basis of Colorectal Cancer  
  
The development of CRC is associated with a multi-step series of genetic changes that 
promote proliferation of the epithelium (1).  The earliest precursors detectable are aberrant 
crypt foci, which lead to the development of adenomas, and subsequently progress to 
malignancy.  Although several common genetic changes have been implicated in the 
adenoma-carcinoma sequence (e.g. APC, K-Ras, DCC and p53 – see figure 1.2), not all 
mutations occur in every cancer.  There are many other genetic defects that can be either 
germ-line or somatic, and the resulting defects subsequently cause chromosomal 
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instability, mis-match repair defects, or methylation defects of DNA (causing epigenetic 
phenomena).  The variation in the underlying genetic changes will result in a unique 
phenotype that causes activation of variable oncogenic mediators (e.g. COX-2, EGFR), 
cell signalling pathways (e.g. WNT pathway, MAP Kinase pathway), and interactions with 
the other cell types that encompass the tumour microenvironment.  Interactions with 
immune cells such as lymphocytes will depend on these genetic alterations resulting in the 
presentation of membrane-bound tumour associated antigens (TAA), and the production of 
homing or growth factors by tumour cells. 
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Microsatellite instability  
Distinct to the changes seen in the adenoma-carcinoma sequence, the genetic basis for 
microsatelite unstable tumours include alterations in hMSH2, hMLH1, BAX and TGFII β. 
Microsatellite instability occurs in Hereditary Non-Polyposis Colon Cancer (HNPCC) 
tumours and also in 15% of sporadic tumours. They are of interest because these tumours 
display characteristics of a different lymphocyte response and different survival statistics 
compared to cancers that have developed via the adenoma-carcinoma sequence.  
Microsatelite-high (MSI-H) tumours display different immunogenic tumour associated 
antigens (2).  A study by Philips et al using immunohistochemistry to assess CD3, CD4 
and CD8 counts in tumour infiltrating lymphocytes found increased expression of CD3 
and CD8 in MSI-H tumours (p = 0.003).  Using PCR they found higher ratios of 
CD8:CD3 in MSI-H tumours (p = 0.016) indicating the cytotoxic nature of these 
infiltrating lymphocytes (3).  More recently, Laghi et al have shown using computer 
assisted image analysis, that CD3+ TIL density at the invasive margin is higher in MSI 
tumours than microsatellite-stable tumours (6.53% versus 2.19%), and increasing 
percentage reduced the risk of metachronous lymph node metastasis (4). 
 
 
1.1.2 Inflammation: progression versus elimination 
 
Using innate and adaptive immunity, inflammatory cells are capable of mounting an anti-
tumour response.  Lymphocytes initiate most of the specific immune response via direct 
cell killing, activation of macrophages, stimulating antibody production and development 
of immunological memory.  But lymphocytes are a diverse group of cells; both cytotoxic 
CD8+ T-cells and CD4+ T-Helper cells have a range of sub-types that display great 
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variation in their functional capabilities ranging from suppression of immune responses 
(and cancer progression) to elimination of tumour cells.  The extent of the lymphocyte 
response will affect the overall neoplastic process, but evasion of the immune response is a 
trait of cancer progression.  Tumour promoting inflammation, due to macrophage or 
lymphocyte production of growth factors or cytokines is the double-edged sword of the 
inflammatory response. 
 
 
1.1.2.1 Evidence for the immune anti-tumour response 
 
A high lymphocyte response at the invasive margins of CRC is an independent predictor 
for a better prognosis.  In 1987 J.R Jass found that a ‘conspicuous’ margin of lymphocytes 
and other inflammatory cells at the peri-tumoural margin could be used as one of four 
factors to accurately predict survival (5).  There is wide variation in the degree of 
infiltration ranging from little or none, to moderate, to pronounced.  Percentage year 
survival was 36%, 65% and 92% respectively.  Jass found that 53% of Dukes A cases 
exhibited a pronounced response compared to 13% of Dukes C cases (6). 
 
Studies such as that by Diederichsen et al in 2003 concentrated on the variation in CD8: 
CD4 ratios. Normal colonic epithelium had a predominance of Cytotoxic CD8+ T-cells 
but the most abundant immune cells in colorectal cancer are CD4-positive T-Helper cells, 
with a CD4+/CD8+ ratio of between 0.8-6.8, median 2.2 (7). Diederichsen discovered that 
a low ratio of CD4+/CD8+, but an overall pronounced lymphocytic response conferred the 
best survival advantage. As previously discussed, tumours that display high levels of 
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microsatelite instability have a higher density of CD3+ T-cells at the invasive margin and 
this correlates to a survival advantage and a decrease in metastasis at presentation (4) (8).   
 
More recently, Pages et al have shown that signs of early metastasis, such as perineural 
invasion or vascular emboli, are inversely related to the presence of effector memory T-
cells, and this also corresponds to poorer survival (9).  Importantly, this group from Paris 
have shown that by using PCR analysis for inflammatory cell gene expression of 39 
markers associated with an anti-tumour response, subsequently analysed by a cluster 
database, tumour recurrence and overall prognosis could be more accurately predicted 
than by conventional histopathological staging (10). This highlights the link between 
understanding more fully the immunological microenvironment, which can help to predict 
disease prognosis, and subsequently direct the planning of treatment (discussed later).  
 
1.1.2.2 Evidence for Tumour-promoting Inflammation 
 
Lymphocytes and tumour associated macrophages (TAMS) produce cytokines, such as 
TNF-α, IL-1, IL-6 and IL-17, that have been implicated in the tumour cell proliferation, 
stromal remodelling and angiogenesis (11) (12).   
 
Chronic disordered inflammatory conditions such as ulcerative colitis and Crohns disease 
have long been linked to the initiation of neoplasia, and the mucosa has been known to 
have increased amount of TNF-α, IL-1 and IL-6 since the 1990s (13).  Since then there has 
been some unravelling of the underlying mechanisms; TAMs release TNF-α that promotes 
tumour cell growth through NFκB signal transduction (14), IL-6 protects cells from 
apoptosis (15)  and in response to hypoxia TAMs release CXCL12 that recruits endothelial 
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cells into the tumour environment (16).  CD4 T-cells play an important role in the 
recruitment of TAMs to the tumour site through release of IFN-γ. 
 
In summary, colorectal cancer develops due to a variety of genetic alterations, in an 
environment including stromal cells, fibroblasts and immune cells all of which play key 
roles in the development of the disease but act together to produce a unique neoplastic 
process.  Understanding these differences, and elucidating patient specific genotypes or 
phenotypes along with (or to aid) improved staging will allow us to progress in treating 
this disease.  We will first consider current treatment modalities and staging, before 
discussing future directions of investigating and treating colorectal cancer and where this 
thesis fits in this process. 
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1.2 Colorectal Cancer Treatment 
 
1.2.1 Introduction to Managing Colorectal Cancer  
 
Colorectal cancer (CRC) is the third most commonly presenting neoplasm to affect 
humans worldwide.  In 2006, 37,514 new cases of CRC were diagnosed in the UK (17). 
When preliminary investigations suggest disease is localised, which accounts for 80% of 
patients, surgery is performed with curative intent. Surgical excision of the tumour with its 
surrounding blood supply and lymphatic drainage is the single most important factor in 
achieving cure from colorectal cancer.  An algorithm for the routine management of 
colorectal cancer is shown in figure 1.3.  Most patients will undergo staging CT scanning, 
and those who have rectal cancer also have an MRI scan of the rectum (18). In the UK, 
treatment options are usually considered by a multi-disciplinary team prior to treatment.   
 
Historically, improved survival has been achieved by improving the quality of surgery, 
improving resection margins, performing total mesorectal excision for rectal cancer and 
optimised peri-operative patient care.  Despite this, half of patients undergoing surgery, 
with or without chemo-radiotherapy, will later develop tumour recurrence due to the 
growth of micro-metastases present at the time of initial treatment. 
 
Surgery provides significant information for staging of the tumour, crucial because any 
further treatment must be evidence based and depends on individual disease prognosis. 
22 
 
 
 
23 
 
1.2.2 Prognostic Indicators in Colorectal cancer 
 
The gold standard for prediction of colorectal cancer outcome remains staging with either 
TNM classification or Dukes Staging (Table 1.1). Histological type, tumour grade or 
differentiation, vascular invasion, and resection margins have all been shown to alter 
prognosis and are routinely used (19).  However, tumours of the same histological type 
and with the same stage at presentation will respond to treatment differently and outcome 
will vary, because of the pathological heterogeneity of disease (discussed in section 1.1). 
 
Table 1.1 Staging of colorectal cancer 
 
 
 
Dukes Staging Pathology 
A Growth into but not through muscularis propria 
B Growth through muscularis propria into serosa 
C1 Regional lymph node spread (not apical node) 
C2 Apical node involvement 
TNM  Pathology 
Tis Carcinoma in situ 
T1 Invades submucosa 
T2 Invades muscularis propria 
T3 Invades subserosa or beyond without other organ involvement 
T4 Invades adjacent organs or visceral peritoneum 
N0 No Lymph node involvement 
N1 1-3 regional nodes 
N2 4+ regional nodes 
M0 No metastases 
M1 Metastases present 
Stage Pathology 
0 Carcinoma in situ – confined to mucosa 
I Submucosa involved 
IIA Serosa involved 
IIB Through Serosa 
IIC Through serosa and spread to nearby organs 
IIIA Into submucosa / muscularis propria plus 1-3 lymph nodes involved 
IIIB 
Through serosa (but not invading adjacent organs) and1-3 lymph nodes involved,  or 
into serosa and 4-6 lymph nodes involved, or into submucosa and 7 or more lymph 
nodes involved 
IIIC 
Through serosa (but not invading adjacent organs) and 4-6  lymph nodes involved,  or 
into serosa and 7 or more lymph nodes involved, or through serosa and into adjacent 
organs with 1 or more lymph nodes involved 
IVA Spread to one organ that is not near the colon 
IVB 
Spread to more than one organ that is not the colon or into the abdominal wall 
peritoneum 
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As well as identifying patients who are at risk of having micrometastases, techniques to 
determine which tumours will respond to a particular therapy are now a key focus.  This 
may be before a treatment has started, or response to treatment once it is underway.  A 
recent example is testing for K-Ras status prior to treatment with EGFR monoclonal 
antibody treatment (discussed in more detail later).  Analysis of any of the factors that 
make colorectal cancer diverse – genetic alterations, cellular molecular pathways exploited 
by cancer cells or analysing the immune response may give prognostic information for 
outcomes or response to therapy.   
 
1.2.3 Adjuvant Therapy 
 
For patients with lymph node metastasis in the histological analysis of the resected 
specimen, additional treatment is aimed at targeting any possible micrometastases.  
Treatment with chemotherapy at this stage incrementally improves the chance of survival.   
 
Historically, most phase 1 or 2 trials for adjuvant therapies have been in patients with 
advanced disease.  The inference has been that therapeutics that control advanced disease 
may eliminate micrometastases. For patients with advanced disease, the use of 5-
fluorouracil has been used since the late 1950s (20), increasing survival from 6 months to 
12 months (21). Combining this with irinotecan then oxaliplatin increases survival to 20 
months (22).   
 
Considering patients who have localised disease with lymph node metastasis, 5 year 
survival is currently 48% (23). There is strong evidence showing survival benefit of 
adjuvant chemotherapy for these patients (24) (25) (26).  The benefit of current 
chemotherapy regimens to increase survival in patients with Dukes B carcinoma has been 
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controversial.  The MOSAIC trial (27) has suggested that combination adjuvant 
chemotherapy (with Oxaliplatin, Fluorouracil and Leucovorin) improves disease free 
survival at 3 years in patients with Dukes B and Dukes C tumours with overall disease free 
survival at 3 years of 87% and 72% respectively. The QUASAR trial which was designed 
to determine whether there was any survival benefit from chemotherapy for Dukes B 
tumours has found the improvement in 5 year survival is from 80% to 83.6% (28).   
 
Newer treatments that are now routinely used include Cetuximab, that targets the 
epidermal growth factor receptor (EGFR). The downstream pathway of EGFR receptors 
involves the MAP kinase pathway that leads to DNA synthesis for cell migration, 
adhesion and proliferation (29). Several trials have shown an improvement in disease free 
survival (30) (31), and it has been approved for treatment of patients with EGFR 
expressing metastatic CRC after failure of treatment with irinotecan since 2004.  The 
current guidelines suggest it can be used as 1st line treatment for advanced disease with 5-
FU, folinic acid and oxaliplatin if the primary has been resected and there are unresectable 
liver metastases, or if the primary or liver metastases may become resectable after 
treatment. It is also recommended as a third line treatment as monotherapy or with 
irinotecan.  The anti-EGFR therapies are not effective if there is oncogenic mutation of the 
KRas gene, as this activates the MAP kinase pathway downstream to EGFR.  To date, no 
trials have shown benefit in patients without frank evidence of advanced disease, but who 
may have micro-metastases.  The FOxTROT Trial is currently underway to assess the 
outcome when pre-operative chemotherapy with or without another anti-EGFR 
monoclonal antibody panitumumab, is given to patients (with wild-type KRas) who have 
locally advanced disease.  Panitumumab is a fully human anti-EGFR MAb. 
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Bevacizumab targets Vascular Endothelial Growth Factor Receptor (VEGFR) to inhibit 
angiogenesis. Used as second line treatment in combination with irinotecan or oxaliplatin, 
overall survival and progression free survival were increased by 2-3 months (32).  It has 
not been recommended as cost-effective use of NHS resources. 
 
Some patients with advanced disease are now cured using current techniques for resecting 
or ablating pulmonary, liver or peritoneal metastasis, but the number of patients dying 
from advanced disease remains high indicating the need for new therapies, and controlling 
micrometastases before advanced disease develops remains the best tactic. The greatest 
advantage of new therapies will be seen in those patients who have a lower burden of 
extra-colonic disease, indicating the need for more trials in patients who do not have 
advanced disease. 
  
27 
 
1.2.4 Novel Treatments 
 
In order to further improve these survival statistics we need to intervene using other forms 
of therapy.  This intervention can be either prior to or after surgical resection. Other 
therapeutics of recent interest includes (i) m-TOR inhibitors which are anti-mitotic (ii) 
Raf-MEK Kinases and (iii) immuno-therapeutics.  
 
m-TOR is a mediator in the phosphoinositide 3-kinase pathway that signals many basic 
cell functions including proliferation (Fig 1.4).  Rapamycin, inhibits m-TOR and has been 
used to block B and T-cell activation to prevent renal transplant rejection.  There has been 
recent interest in using m-TOR inhibitors to prevent cancer cell proliferation, and clinical 
trials are ongoing targeting renal cell cancers (33).  A study using colorectal cancer cell 
lines has shown sensitivity to rapamysin (34), and this is a possible area for further study. 
 
Raf-MEK kinases are also part of the MAP kinase signalling pathway (which plays a 
central role in cell proliferation), but they are downstream to both EGFR and Ras 
signalling.  Pre-clinical studies had shown a decrease in downstream ERK signalling, but 
the Phase II trials reported to date have yet to show a significant increase in survival from 
advanced colorectal cancer (35).   
 
Immunotherapeutic techniques have been investigated for the treatment of colorectal 
cancer since the early 1970s (36) .  Historically, colorectal tumours have not readily 
shown immune-mediated spontaneous regression, in the way that other tumours have, such 
as melanoma (37) (38).  However, the documented presence of both colorectal tumour 
antigens and an intra-epithelial T-cell infiltrate gives promise that CRC is not altogether 
poorly immunogenic.   
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There are individual stories of success, but to date there has not been clinically relevant 
success in the treatment of colorectal cancer.  T-cell based immunotherapy has recently 
been licensed for use in prostate cancer (39) and this gives promise for other tumours. Our 
knowledge of T-cell function, their interactions and their diversity has increased 
exponentially in the last decade, and its implications on the tumour immune 
microenvironment and immunotherapeutic techniques are discussed further in section 1.4.  
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There are several important aspects to consider regarding current and future colorectal 
cancer trials. Firstly, as already stated, we need more trials in patients who do not have 
advanced disease, who have possible micrometastases but a lower burden of disease. 
Secondly, there is current interest in neoadjuvant trials where a portion of an already 
proven chemotherapy regime is given prior to surgery (e.g. the Foxtrot trial) with the aim 
to enhance the effect of current chemotherapy without the wait for surgery having a 
negative impact. Thirdly there is current interest in ‘window of opportunity trials’ where a 
new therapeutic is given in the window between diagnosis and surgery, with the benefit of 
again targeting more patients with a lower burden of disease rather than patients with 
advanced disease who have tumours that are already refractory to other treatment 
modalities.  The benefit of neoadjuvant therapy and window trials are that tumour can be 
harvested for analysis after treatment has been given, at the time of surgery. 
 
In all of these areas of development of new therapeutics, biomarkers of the response are 
essential.  For the molecularly targeted therapies, measurement of downstream molecules 
can be used to provide proof of concept and response to treatment.  For 
immunotherapeutic techniques, analysis of the immune microenvironment is obvious, but 
all therapies including molecularly targeted therapies, chemotherapy or radiotherapy will 
have an effect on the local immune response. 
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1.3 Biomarkers 
 
 
 
1.3.1 Definitions and Principles of Biomarker Discovery 
 
In 2001 the ‘Biomarkers Definitions Working Group’ which was set up by the National 
Institute for Health concluded that a biomarker is “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” (40).   
 
Biomarkers may have single or multiple functions, including screening, diagnosis, staging, 
prognosis or surveillance of a pathological condition.  Prediction of response to 
intervention is another potential role of a biomarker.  For example, in 2008 Karapetis et al 
studied 394 patients with metastatic CRC who were randomly assigned treatment with 
Cetuximab (anti-EGFR), or not, and found that patients with wild-type K-ras had a 
significant improvement in progression-free survival compared to no difference in patients 
with K-ras mutations (41).  A similar study has shown similar results for Panitumumab 
(also anti-EGFR) (42).  K-ras typing is now routinely performed as a predictive biomarker 
prior to treatment with these therapies. 
 
Biomarkers can also be used to monitor the effect of a treatment.  In clinical trials they can 
be particularly useful if they are a measurable product of the pathological process, as they 
can help establish whether using a specific treatment can be explained by the alteration in 
the underlying pathophysiology.   
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The processes involved in developing a biomarker have been outlined by Cancer Research 
UK (Appendix 8.1). The strategy for development of a biomarker must start with ensuring 
there is an unmet clinical requirement (43).  In the circumstance of this work, the unmet 
clinical requirement is a test, or series of tests, that can confirm if there are TIL present 
that have the ability to mount an anti-tumour response.  Given the complexity of the 
immune system, it is likely that there will not be a solitary test that could be performed 
that could identify whether an enhanced anti-tumour attack is likely to have taken place.  
Lymphocyte number alone is meaningless if the lymphocytes present are dampened down 
or anergic.  
 
The next question of whether the work is focussed on developing a biomarker or assay that 
will be used on clinical material. If so, there should be the means for collecting the clinical 
material (blood/tissue etc) that will be required.  If tissue has to be collected in a 
standardised way or under certain conditions then it is important that these methods will 
be reproducible.  For the work undertaken in this research, there were no stores of frozen 
or cultured TIL that could be used for outcome correlation studies. This research, and any 
subsequent similar analysis would require the use of fresh, live TIL.  
 
The next stage involves the development of a reproducible assay, and this should be done 
using samples representative of the target population.  For this research we used assays 
that are standard techniques when using them for PBL, such as flow cytometry and 
ELISA, but use with TIL would require refinement. Analysing a combination of cell 
surface markers associated with a good functional response, or indeed those associated 
with anergy could provide immunological outcome measures.  Developing this type of 
outcome measure would also aid understanding of the biological processes involved, and 
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its subsequent measurement could provide ‘proof of concept’ that the immunological 
intervention is altering the immune response in the tumour microenvironment. 
 
The next stage known as ‘Biomarker Discovery stage 1’ involves defining the biomarker 
distribution on specimens that are representative of the target population.  The target 
population we chose was all-comers with colorectal cancer and we did not limit the 
inclusion to a specific stage of the disease.  Assays were defined and Standard Operating 
Procedures detailed. 
 
‘Biomarker discovery stage 2’ involves retrospectively analysing the relationship between 
the biomarker and clinical outcome, but this may not be assessed until a Phase III trial 
takes place. During most phase I and II trials, the aim is to establish dose and drug 
activity, so biomarkers can be used to show an effect of drug activity and do not 
necessarily have to correlate to long term survival benefit.  
 
1.3.2 Immunological Biomarkers  
 
Biomarkers used as surrogate end-points in immunotherapy trials should be able to 
identify a long-term treatment benefit, but they may have other important functions too, 
such as stratifying best treatment options for individual patients, or identifying 
mechanisms of underlying pathology or drug action.   
 
Recently, several biomarkers used to either predict the response, or describe the effect of 
immunotherapy have been reported.  In 2008, Dudley et al reported on the use of 
biomarkers to predict the response of adoptive transfer of autologous TIL (that were 
tumour antigen specific) in patients with melanoma who had previous lympho-depleting 
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chemotherapy/chemo-radiotherapy (44).  They hypothesized that the lympho-depletion 
reduced both the number of endogenous inhibitory T-Regulatory cells and increased the 
availability of homeostatic chemokines that could initiate proliferation of the infused TIL.  
They measured the telomere length of TIL being infused as this can predict their 
proliferative potential.  They found a positive correlation between telomere length and 
response to therapy (as determined by radiological disease progression). They also found 
higher levels of IL-7 and IL-15 in patients after lymphodepletion with chemo-radiotherapy 
than chemotherapy alone. The response rate in patients who had autologous TIL transfer 
after chemotherapy was 49%, and after chemo-radiotherapy was 72%.   
 
Several studies have used peripheral blood lymphocytes to assess antigen specific IFN-γ 
release or proliferation assays (45) (46) (47) (48) (49) as immunological biomarkers as 
end-points.  Few studies use TIL.  A study by Xu et al in 2008 validated the use of IFN-γ 
ELISPOT, IFN-γ RT-PCR, and antigen-specific HLA-A2 tetramer flow cytometry for TIL 
cell lines from melanoma patients (50).  Their aim was to use these methods to monitor an 
active specific immunization trial.  
 
1.3.3 Principles to analyse the immune response in colorectal cancer 
 
1.3.3.1 Cell type for analysis 
Lymphocytes are the most abundant immune cells and mediators of the specific immune 
response.  Analysing TIL specific to one peptide (eg CEA) would exclude a large majority 
of the TIL population.  The benefit of looking at whole population of TIL is that it includes 
all subtypes that may be interacting with each other.  The subtypes present are of interest 
as they may capable of an anti-tumour response, or conversely dampening down the 
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immune response. Analysing cell surface markers can help elucidate these functional 
differences, but in order to do this we need to use fresh live TIL as cell surface markers 
may change with extended culture or with freezing processes.   
 
1.3.3.2 Functional tests for Lymphocytes 
Elucidating the phenotype of T-cells with multicolour flow cytometry allows the analysis 
of cell surface markers for T-helper, Cytotoxic T-cells, and T-regulatory cells. There are a 
host of other T-cell markers measured by flow cytometry, that may indicate a functional 
difference between cells; such as markers for naive versus memory cells, markers for T-
cell lineage (αβ or γδ), and markers of activation (CD25, CD69, or CD71).  Markers of T-
cell homing can identify cells that will migrate to a particular tissue and cells with homing 
markers in common may have similar functional capabilities. 
 
T-cell responses are generally mediated by cytokine release, and this occurs only after the 
cell has been stimulated.  In vitro methods of stimulating T-cells include, adding antigen to 
which the T-cells in question have a pre-determined antigen receptor on the T-cell receptor 
(TCR) complex, or methods that will activate the whole T-cell population.  These include 
phorbol myristate acetate (PMA) (a known mitogen), CD3 and CD28 monoclonal 
antibodies that directly activate the TCR, or OKT3 which is a soluble form of CD3 
monoclonal antibodies.  The addition of the cytokine IL-2 can enhance these responses by 
signalling pathways for growth and differentiation.  Activation of the TCR causes 
expression of the IL-2 receptor on the T-cell membrane. 
 
There are several methods for detecting cytokine release. Methods such as ELISPOT or 
intracellular cytokine staining with flow cytometric analysis can measure release from 
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single cells. Methods such as ELISA or LUMINEX can measure release from a whole T-
cell culture.  
 
ELISA and ELISPOT both use pairs of antibodies (catching and detecting antibodies) 
followed by detection of a colour reaction. However, ELISPOT will detect the number of 
cells in a culture plate that produce any amount of the cytokine of interest, whereas ELISA 
will detect the concentration of the total amount of cytokine present in the supernatant. 
Therefore, ELISPOT is good for detecting the number of active cells even if a very small 
concentration of cytokine is released and ELISA will often be negative in these cases. 
However, ELISPOT will give the same result if a given number of cells all produce a very 
small amount or a very large amount of cytokine.  Both techniques are well established for 
the detection of well known cytokines such as IFN-γ.   
 
Intracellular cytokine staining is a newer technique that involves culture of T-cells with an 
intracellular transport inhibitor to arrest the cytokine inside the cell, followed by cell 
fixation and permeabilisation to allow antibody to the cytokine to enter cells. This method 
can allow detection of more than one cytokine at a time, but low frequencies of cytokine 
production can be difficult to detect.  At the time of undertaking this study, intracellular 
cytokine staining was a method that was not as robust or as widely used as ELISA or 
ELISPOT.  LUMINEX is a bead array system that is based on flow cytometry but which 
can perform several analyses of cytokines present in supernatant at once. The benefits 
include that only a small volume of culture would be required, but the main disadvantage 
was that a LUMINEX device was not available to us at the time of study. 
 
The methods that best suit analysing properties of TIL would be addressed in the study, by 
undertaking assays of ELISA, ELISPOT and intracellular cytokine staining. In order to 
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determine specific markers of T-cells that we would want analyse, the following section 
considers what we know about T-cell biology to date.  
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1.4 T-Lymphocytes 
 
1.4.1 Introduction to T-cells  
 
T-cells are a sub-group of lymphocytes involved in cell mediated immunity (51).  The 
production of these cells begin in fetal life with hepatic progenitors, and is maintained 
throughout adult life by bone marrow derived haematopoietic progenitors, both of which 
are mobilised to the thymus for differentiation into T-Lymphocytes (52) (53). The process 
of differentiation is continued in peripheral tissues and results in the production of various 
sub-groups of T-cells that have multiple different functions (54). They are of vital 
importance in the body’s lymphocyte response to eliminate antigen, as shown by studies 
on thymectomised neonatal mice that have significantly impaired cell mediated immunity 
resulting in viral, mycobacterial and fungal infections (51) (55). 
 
1.4.2 Early T-Cell differentiation 
 
During early development, T-cell progenitors diverge into one of two distinct lineages.  
This is based on genetic recombination of T-cell receptors (TCR) to either αβ or γδ 
selection (figure 1.5).  Once committed to γδ TCR combinations, γδ T-cells mature and 
leave the thymus to undertake homeostatic functions in the skin and the gut (56).    
 
The TCR- β gene loci undergoes rearrangement, to produce a complement of epitopes that 
will recognise antigen.  Only thymocytes with a functional receptor that will bind antigen 
on presenting cells (APC) above a certain threshold will persist, in a process of positive 
selection, with the remainder undergoing apoptosis (57).  Conversely, if the β-TCR binds 
too strongly to endogenous antigen, negative selection occurs (58) (59).  This is an 
important step in developing central tolerance.  The β-dimer then pairs with a facilitating 
38 
 
α- receptor to form the ‘pre-TCR’, and through a variety of micro-environmental factors, 
such as CD3 and Notch signalling, they become committed αβ-TCR cells that expresses 
CD4 or CD8 (54) (56). Thymic epithelial cells have a high rate of turnover and this 
provides the source of self- antigen that will allow the development of central tolerance 
(60).  
 
 
A subpopulation of CD4+ cells, that are important for maintaining self-tolerance in the 
periphery, T-regulatory cells,  are also generated in the thymus, by a process that involves 
CD28 co-stimulation (61).  Conventional CD4+ T-cells undergo further differentiation 
throughout their life-time in the peripheral circulation (figure 1.6).  
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1.4.3 T-cell structure, activation and function 
 
The functionally important component of the T-cell membrane, the TCR, is a hetero-dimer 
of either αβ or γδ portions co-expressed with the accessory protein CD3 (figure 1.7).  80% 
of T-cells are of αβ lineage (56).  The structure of this lineage consists of a ‘constant’ 
membrane-anchored region and a’ variable’ extra-membrane region (62).  The variable 
portions of α and β dimers are similar to the Fab fragments of immunoglobulin, and 
recognise antigen fragments displayed on major histocompatibility complex (MHC) (63).  
Their clonal diversity can be appreciated by the fact any particular antigen will be 
recognised by only 1:5,000 to 1:50,000 T-cells (64).   
 
γδ T-CELLS 
αβ CD4 T-CELLS
αβ CD8 T-CELLS
FOXP3
CD25
CTLA-4
GITR
CD69
CD25
CD71
HLA-DR CELL SURFACE 
MARKERS
FOXP3
CD25
CTLA-4
GITR
Fig. 1.6 Peripheral T-cell differentiation and cell surface marker expression.
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MHC class I molecules, expressed by most cells in the body bind CD8+ cells, and MHC 
class II molecules, expressed by Antigen Presenting Cells (APC) such as dendritic cells 
(DC) in skin, lymph nodes, the spleen and mucosal Langerhans cells, have the ability to 
bind CD4+ cells.  DC have the potential to take up proteins from sites of tissue damage, 
and re-present them on the surface as short peptide fragments bound to MHC.  DC can 
migrate to lymph nodes and interact with T lymphocytes forming a TCR-MHC-peptide 
complex.  Thus CD4+T cells are activated, proliferate and then go on to activate cytotoxic 
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CD8+T-cells.  Cells that present the same peptide on MHC class I can then be eliminated 
by CD8+CTL.   
 
The TCR complex is closely linked to the glycoprotein CD3 (65).  The phosphorylation of 
CD3 occurs at regions known as immuno-receptor tyrosine-based activation motifs 
(ITAMs), and allows the docking of the enzyme ZAP-70 which is essential to initiate 
signalling and activation of the T-cell towards prompting proliferation (66).    
 
Co-stimulatory molecules are essential in this process, and without them T-cells are 
rendered anergic (66).  CD28 is a molecule that performs this function effectively, by 
binding to its ligands beta-7.1 (CD80) and beta 7.2 (CD86), present on the APC membrane 
(67). 
 
As outlined in table 1.2, various subsets of T-cell exist, which vary extensively in their 
phenotype and function.  Most activation of CD4+ T-Helper cells will occur within lymph 
nodes, and effector cells then preferentially enter their target tissue.  Activated T-helper 
cells interact with naive CD8 cytotoxic T-lymphocytes (68).   CD4+T-helper can 
potentially contribute to an anti-tumour response in several ways, directly by cell-cell 
interactions with APC and CD8+ T-cells, and by cytokine release which is important for 
the priming of CD8+ cells in order to produce a maximal cytotoxic effect.  They have also 
been shown to have the capability of killing malignant cells in the absence of CD8+ T-
cells, by a process that involves the recruitment of macrophages (69). 
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Table 1-2 Functional sub-groups of T-Lymphocytes. 
 
 
 
 
 
 
 
 
 
Population Cell Surface Phenotype Function 
Naive αβ T-cells CD3+CD45RA+TCR αβ Cell mediated immunity 
TEM (Effector 
memory) 
CD3+CD45RO+CD62L-CCR7- 
Effector response 
(periphery) 
TCM (Central 
memory) 
CD3+CD45RO+CD62L+CCR7+ 
Effector response 
(lymphoid) 
TH1 (T-helper 1) CD3+CD4+ 
Cell mediated immunity, 
macrophage activation, 
IFN-γ production 
TH2 (T-helper 2) CD3+CD4+ 
B-cell activation, IL-4, IL-
5, IL-13 production 
TH17 (T-helper 17) CD3+CD4+ 
Hyper-inflammation, IL-
17 production 
Treg CD3+CD4+CD25+FOXP3+ 
Contact dependant 
suppression, TGF-β and 
IL-10 production 
T-regulatory type 1 CD3+CD4+ 
Immune regulation, IL-10 
production 
NKT (Natural Killer 
T-cells) 
CD3+CD56+ 
Multiple roles in immune 
response. Pathogenic in 
asthma. Produce IFN-
γ/TNF or IL-4/IL-13 
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1.4.4 Tolerance 
 
 
Tolerance describes a state of unresponsiveness by immune cells.  The immune system 
randomly produces a large number of potentially self-reactive antigen-specific T-cells that 
if left unchecked, could cause harmful self-destruction.  There are various levels at which 
tolerance develops.  The first, as previously stated, is in the thymus by negative selection 
of βTCR that binds too strongly to self antigen, but some low affinity auto-reactive T-cells 
escape destruction.   
 
The second level of tolerance development is achieved in the periphery.  The methods that 
promote peripheral tolerance include (i) T-cell elimination (ii) T-cell anergy (iii) T-cell 
suppression, and (iv) ignorance due to lack of MHC expression.   
 
The pathways that result in T-cell elimination in order to produce tolerance is poorly 
understood.  We have known since 1991, by mice studies, that tolerance to 
Staphylococcus Aureus toxin was mediated by apoptosis (70). In 1999 it was shown in 
mice studies that T-cell apoptosis (through activation–induced death) is required to 
develop allograft tolerance (71).  More recently, it has been shown that T-cells express a 
type of TNF receptor called Death Receptors (DRs) that are involved in T-cell apoptosis 
as a mediator of tolerance.  When ligand attaches to the DRs, there is recruitment of 
adaptor molecules, and it is the type of adaptor molecule which determines whether the 
cell will undergo survival and activation (via NFκB) or apoptosis (via caspase-8) (72).    
 
T-cell activation is dependent on MHC-TCR binding in presence of co-stimulatory 
molecules and their ligands, expressed by T-cells and dendritic cells respectively. Co-
stimulatory molecules include CD28 on the T-cell membrane, which, as previously 
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mentioned binds to β7 on the APC membrane.    T-cell anergy can be induced when co-
stimulatory signals are absent, or when negative receptors such as Cytotoxic T-
Lymphocyte Receptor-4 (CTLA-4), which  is upregulated when T-cells become activated, 
binds to β7 (73). Mice deficient in CTLA-4 die from autoimmune disease (74).  However, 
it is not absolutely required for the induction of tolerance and more recently the role of 
another co-inhibitory molecule, PD-1 has been described as having an essential role in the 
development of anergy, again by binding to β7 (75) .  
 
The most recent studies attempting to unravel the mechanisms promoting peripheral 
tolerance attempt to elucidate the interaction between dendritic cells and suppressor T-
Regulatory cells (TREG).   The mechanisms by which TREG are thought to induce tolerance 
include suppressor cytokine expression with TGFβ (76) and IL-10 (77), and cell-cell 
contact mechanisms involving CTLA-4 on TREG and β7 on effector T-cells (78).    
 
Cancers are thought utilise several other mechanisms to induce tolerance, such as absent 
or reduced MHC I expression, an absence of the inflammatory cytokines normally 
required to prime DCs to act as APCs resulting in DC promotion of T-cell anergy, and 
accumulation of myeloid-derived suppressor cells (immature macrophages, granulocytes 
and DC’s) that impair the ability of cytotoxic T-lymphocytes to produce the interferon-γ 
that is required for an anti-tumour response (79). 
 
1.4.5 Cytokines, and Effector responses 
 
Cytokines are a group of over 200 small protein-signalling molecules (approx. 8-80kDa) 
released by lymphocytes and neoplastic cells, which act in an autocrine or paracrine 
fashion.  T-helper cells can be sub-divided by the cytokines they produce.  T-helper 1 cells 
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produce interferon-γ (IFN-γ), tumour necrosis factor-β (TNF-β) and interleukin-2 (IL-2) 
and these responses promote cell-mediated responses with activation of macrophages and 
antibodies involved in opsonisation (80).  The development of TH1 cells from naive T-
cells is dependent on IFN-γ (from other TH1 cells) and IL-12 (from macrophages). 
 
T-helper 2 cells produce IL-4, IL-5, IL-10 and IL-13 and induce the humoral immune 
system with antibody and allergic responses.  IL-4 induces B-cell proliferation, and IL-4 
and 5 are important for eosinophilic inflammation and the allergic response (54) (80).  IL-
4 also triggers TH2 cell proliferation, but development of TH1 responses are inhibited 
directly by IL-4 and IL-10 (80). 
 
There has been a recent discovery of a 3rd set of effector cells, TH17 cells that produce IL-
17 (81) (82). They also produce IL-17F, IL-6 and TNF (54) (83).  IL-17 causes potent 
activation and proliferation of neutrophils to clear pathogens that have not been destroyed 
by a TH1/ TH2 response.   These cells were initially identified when it was discovered that 
IFN-γ deficient mice could still develop autoimmune diseases, raising the likelihood there 
was a sub-population of T-cells initiating the pathology other than TH1 cells (84). 
 
 
1.4.6 Regulatory T-cells 
 
Circulating CD4+ lymphocytes include a subset of regulatory T lymphocytes (TREG) that 
can either occur from thymic differentiation (naturally occurring TREG ) or as a product of 
differentiation in the periphery after either repeated activation or interaction with 
suppressing DCs. TGF-β induces DC to express CD73, which in turn generates adenosine 
that has been shown to generate anergy in T-cells and also control their differentiation into 
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TREG (85).  In-vivo animal models have demonstrated that induced or transferred TREG 
have the ability to inhibit autoimmune disease or transplant rejection (86), or suppress the 
anti-cancer immune response.  
 
The presence of a regulatory subset of cells had been proposed for several decades, but 
confirmation of their presence was hampered by a lack of immune markers to identify 
which CD4 cells have this function.  More recently, certain phenotypic features have been 
used as markers of TREG (87).  The IL-2 α chain (CD25) is expressed on populations of 
naturally occurring TREG.  It can also be expressed on TREG that produce IL-10 and have 
evolved suppressive functions in the periphery.  Unfortunately some activated effector 
cells may also express CD25.  Many studies now differentiate between CD25- high 
expression, which is thought to be associated with regulatory function, and CD25-Low 
expression, which can be present on effector CD4 cells. 
 
Other surface molecules expressed by TREG include the glucocorticoid induced TNF 
family receptor (GITR) and cytotoxic T lymphocyte antigen-4 (CTLA-4).  However, these 
too can be displayed by activated T-cells not involved in immune regulation.  The 
transcription factor foxp3 is thought to be important in the programming of cells that 
develop regulatory functions, and to date this appears to be the most (but not completely) 
specific marker to identify TREG.  Antibody reagents specific for this factor that allow 
detection of TREG only became commercially available during the period of study.   
 
Foxp3 functions to down regulate the T-cell response to antigen.  Effector and regulatory 
T-cells possess the T-cell receptor (TCR), which binds to antigen, and in turn interacts 
with the nuclear factor of activated T cells (NFAT) to stimulate the IL-2 gene, to produce 
IL-2, which initiates clonal expansion.  Foxp3 interacts with NFAT and the IL-2 gene to 
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inhibit this transcription (88).  Humans with the x-linked syndrome “Immunodysregulation 
Polyendocrinopathy and Enteropathy” have mutations of the foxp3 gene, and 
phenotypically they have uncontrolled T-cell proliferation resulting in autoimmune disease 
(89).  A study of patients with ovarian cancer (90) has shown that 90% (+/-8%) of tumour 
infiltrating lymphocytes (TIL) that stained CD4+CD25+ were also positive for foxp3, and 
100% of TIL that were positive for foxp3 were also CD25+ . Interestingly, this study has 
shown by staining of ovarian tumour with CD25, CD8 and foxp3, that many of the TREG 
were in very close proximity to the cytotoxic T-cells, suggesting physical contact between 
these cell types. A further study in patients with metastatic melanoma has also suggested 
that suppression by TREG is produced by a cell contact mechanism (91).   
 
The most distinctive functional features of TREG are their ability to suppress the function of 
other T lymphocytes.  This includes the ability to release suppressive cytokines such as IL-
10 and TGF-β and to suppress the proliferation and effector function of THC (for example 
suppression of IFN-γ production) (92) (91).  In co-culture experiments, CD4+CD25+ cells 
inhibited both IFN-γ release and proliferation of CD4+CD25- and CD8+ T-cells (93). In 
animal models, removal of CD25+ cells enhances anti-tumour immune responses (94). 
 
TREG have been identified in both blood and in tumour from patients with cancer, including 
melanoma, breast, pancreatic, ovarian and lung cancer (95) (96).  For example, patients 
with pancreatic or with breast cancer, have an increased proportion of CD4+CD25+ T 
cells compared with healthy individuals.  In these patients, about 20% of both TIL and 
draining lymph node lymphocytes (LNL) were CD4+CD25+.  These putative TREG from 
blood, tumour and lymph nodes showed similar properties, releasing IL-10 and TGF-β, but 
not IFN-γ in response to stimulation.  At the time of planning this study, little was known 
about the functional properties of CD4+ TIL and lymph node lymphocytes (LNL) in 
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colorectal cancer (CRC), or whether there is a significant infiltration of TREG, in patients 
with CRC.  A study by Sasada et al in 2003 had shown a slightly higher prevalence of 
CD4+CD25+ cells in peripheral blood of 48 patient with colorectal cancer, but this was 
compared to only ten healthy patients who were much younger (97). 
 
As discussed previously, JR Jass realised the importance of lymphocytic infiltration (6), 
but it is becoming clear that the abundance of lymphocyte infiltration is not the only factor 
important in immune regulation of the tumour microenvironment, but the exact 
composition of lymphocyte subsets in terms of function will determine the degree of 
tumour cell death.   
 
Since this study was undertaken, there has been significant interest in the presence of TREG 
in CRC, but there have been conflicting findings.  Bernt et al in 2008 (98) performed a 
proteomic analysis of colonic mucosa in patients with both colorectal cancer and 
ulcerative colitis versus controls, and had shown the number of CD4+CD25+ cells is 
decreased in colorectal cancer specimens, but increased in ulcerative colitis, with a 
difference in the relative frequency of 2:6 respectively (p=0.038). 
 
A study by Clarke et al in 2006 (99), looked at the frequency of TREG in PBL and 
mesenteric lymph node of patients with colorectal cancer.  They specifically looked at the 
CD25High subset, thought to more specifically represent TREG cells, and found the 
frequency in colorectal cancer and control groups to be less than 2% of CD4+ cells, but it 
was higher in colorectal cancer patients (1.13% versus 0.46%).  The study size was small 
with just 12 patients, and they did not examine tumour-infiltrating lymphocytes.  Baecher-
Allan et al described the concept of CD25High cells in 2001 (100).  They described the 
CD25 High subset as being those cells stained more intensely than the CD4 negative 
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CD25 positive population (Fig. 4.6).  The current literature varies between measuring 
CD4+CD25 High and Total CD4+CD25+ subsets, but this is important to distinguish as 
CD25 Low cells are probably activated, functioning effector cells. 
 
Most recently, Salama et al have used tissue microarrays and immunohistochemistry to 
analyse FOXP3 density in colorectal cancer versus normal mucosa (101).  They found that 
a high FOXP3 density in normal mucosa was associated with a poorer prognosis, but that 
a high density of FOXP3 in tumour was associated with a better prognosis.  This is 
contradictory to findings in other solid tumours such as ovarian carcinoma (90).  A 
preclinical study in mice has shown that CD4+CD25+ regulatory T-cells can induce 
regression of colitis induced tumours (102), but it has been known since 1999 that IL-10 is 
essential in inhibiting intestinal inflammation (103).  Of interest, recent studies have also 
shown that TREGs can induce regression in intestinal tumours that have been induced by 
APC deficiency (104). This was associated with an increase in apoptosis, but these 
unexpected findings require further functional studies to discover the underlying 
mechanisms involved. 
 
1.4.7 T-Cell Homing 
 
1.4.7.1 Homing Factors 
Homing factor ligands are released in peripheral tissues and form a concentration gradient 
that causes migration of T-cells (105).  They are important for modelling the structure of 
the immune micro-environment. They can be characterised as either homeostatic or 
inflammatory.  Interestingly, certain groups of homing receptors are associated with 
different T-cell functions, for example TH1 versus TH2 responses. Additionally, some 
receptors are associated with particular tissues.  
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Cell migration from the venules into surrounding tissues depends on signalling and 
adhesion molecules that are expressed by endothelium.  Firstly, adhesion molecules such 
as P-selectin (on platelets) and E-selectin (in endothelial cells) slow the lymphocytes and 
bring them to a halt on the endothelial surface (106).  Selectin expression can be induced 
by both acute inflammation and by neoplasia.  The dominant ligand for the selectins is 
PSGL-1.  Once halted, the lymphocyte can interact with cytokine signalling molecules 
known as chemokines that are expressed on the endothelium.  The composition of a T-cell 
infiltrate varies depending upon the specific tissue site to which the cells have migrated.  
There are complex interactions between endothelial cells, stroma and the inflammatory 
infiltrate that result in a constantly changing dynamic process, facilitated by chemokines, 
integrins and selectins.   
 
Chemokines are short peptides of 67 to 127 amino acids presented on proteoglycan 
components of the extra cellular matrix.  Nearly fifty chemokine polypeptide ligands are 
described, binding to twenty known receptors (107).  The latter are part of a larger family 
of seven-trans-membrane domain G-coupled-protein receptors (GCPR) (Table 1.3).   
 
The human chemokine family consists 4 subfamilies (CC, CXC, XC, and CX3C), 
depending on the position of cysteine residues within the amino acid sequence on the 
NH2-terminal (108).  CXC chemokines have an amino acid between the first two cysteine 
residues, whereas CC chemokines have adjacent cysteine residues. XC chemokines lack 
cysteines one and three of the regular structure and CX3C has three amino acids between 
the first two cysteine residues.  It is this NH2-terminal that is responsible for chemokine 
activity.  Proteases that cleave this terminal, such as CD26 and matrix metalloproteinases 
(MMPs) may alter the chemokines present (109).  Lymphocytes with common effector 
function, such as secreting certain cytokines, typically express some chemokine receptors 
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in common.  Three broad groups of chemokines exist, homeostatic, inflammatory and dual 
function.
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Homeostatic chemokines play a role in the trafficking of naïve T-cells between high 
endothelial venules and lymph nodes, as well as other lymphoid sites, such as spleen and 
mucosa associated lymph node tissue (MALT) (110).  They are produced continually, and 
promote routine immune surveillance by bringing naïve T-cells in contact with dendritic 
cells within lymphoid sites.  Homeostatic chemokines, such as CXCL12, CXCL13, 
CCL19 and CCL21 tend to bind one specific ligand (111) (110). 
 
T-cells are then primed, so that inflammatory chemokines can facilitate transfer to sites of 
inflammation in peripheral tissues.  Inflammatory chemokines include many of the CXCL 
and CCL chemokines, and tend to activate a broad selection of chemokine receptors (111). 
Chemokine expression varies between tissue types and states of disease.  T cells also 
produce multiple inflammatory chemokines, so may be responsible for amplifying the 
immune response.   
 
Dual function chemokines, as their name suggests, have both homeostatic and 
inflammatory roles, but again tend to activate a single chemokine receptor, for example, 
CXCL16 binds to CXCR6 and is involved in T-cell lymphopoesis and extravasation at 
inflammatory sites (111).  
 
Chemokine receptors are seven-transmembrane domain G-protein-coupled receptors 
(GPCR) that can be expressed by lymphocytes (Figure 1.8), and which bind to chemokines 
and activate the expression of integrins on the lymphocyte surface, ultimately resulting in 
migration.  When the appropriate chemokine ligand binds, GDP is substituted for GTP, 
which causes dissociation of the G-protein subunits.  G then binds to Phospholipase C, 
which in turn cleaves Phosphatidyl Inositol Biphosphate (PIP2) into Inositol Triphosphate 
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and Diacylglycercol, setting off a variety of signalling cascades that produce various 
cellular responses such as chemotaxis (112).   
 
 
1.4.7.2 Cytokines and chemokines in colorectal cancer progression 
There is a large pool of pro- and anti-carcinogenic factors present in the microenvironment 
and deciphering the overall function of this myriad is difficult. As previously discussed in 
detail, a TH1 response is associated with an anti-tumour response mediated by IFN-γ 
release.  However, cytokines secreted from tumour cells can be mitogenic and angiogenic.  
One such example includes tumour necrosis factor (TNF), which can be detected in 
malignant cells in CRC, and in animal models it promotes invasion (113).  Conversely, 
TNF also induces production of lymphocyte attracting molecules, chemokines, which in 
turn can either promote or inhibit angiogenesis.  Tumour associated macrophages can 
secrete IL-10 and PG-E2 (which confer resistance to tumour cells against an effector 
lymphocyte response), MMP-2 and MMP-9 (which promotes metastasis), and IL-1 (which 
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initiates release of VEGF to encourage angiogenesis).  Lymphocytic production of IL-6 
has been linked to progression of several tumours (114).   
1.4.7.3 Lymph Node Homing 
A multistep adhesion cascade is responsible for the entry of T-cells from the blood stream 
to peripheral lymph nodes (Figure. 1.9).  This is initiated by the binding of L-selectin 
(CD62L) on the naïve T-cell membrane to peripheral node adressin (PNAd) on the 
endothelium of specialised high endothelial venules (115).  Activation of CCR7 on the 
naïve T-cell membrane is mediated by its ligands CCL21 and CCL19.  CCR7, and perhaps 
CXCR4, trigger integrin LFA-1 activation via intracellular Gαi-protein-linked signals, to 
promote binding to ICAM-1or ICAM-2 on the endothelial cell surface and this causes 
arrest of the T-cell (116) (117).  Studies have shown that in mouse models, the absence of 
CCR7 is associated with complete inhibition of migration of naïve T-cells into peripheral 
lymph nodes. 
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Following T-cell arrest, chemotaxis across high endothelial venules (HEV) occurs, and T-
cells then randomly move around the lymph node interstitium within the T-cell zones, and 
come into contact with dendritic antigen presenting cells.   
 
CXCR5 is responsible for B cell access to B cell follicles in lymph nodes.  In addition, 
CXCR5 is activated by CXCL13 in a small subpopulation of CD4+ T cells, follicular B 
helper T cells, which also localise to the B cell follicle and aid the antibody response to 
antigen. 
 
1.4.7.4 Homing to Peripheral Tissues 
Following further T-cell differentiation, there are two examples of memory T-cells 
depending on CCR7 status, both of which recognise antigen on APC.  The smaller subset 
of CCR7+ central memory T-cells are responsible for surveillance in the blood stream and 
secondary lymphoid tissues.  These cells are long-lived and are responsible for ‘recall’ 
responses on repeated antigen presentation.  One subset of central memory cells, 
CCR7+β7+ T-cells migrate to peyers patches.  The majority of memory T-cells are CCR7-
effector memory T-cells, which migrate through peripheral tissues, and can interact with 
tissue sites particularly when there is up-regulation of expression of inflammatory 
chemokines.   
 
In homeostasis, the adhesion molecule PSGL-1 present on T-cell membrane binds to its 
ligands E- and P-Selectin. Other adhesion molecules associated with peripheral homing 
include cutaneous lymphocyte-associated antigen (CLA), which is responsible for skin 
specific homing, and MAdCAM-1 that is involved in gut homing. 
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1.4.7.5 Homing to sites of Inflammation 
The integrin VLA-4 (along with LFA-1) is involved in tethering and rolling of 
lymphocytes at sites of inflammation by interacting with VCAM receptors on the 
endothelium. Again, migration then occurs due to the presence of inflammatory 
chemokines.  A study from 1998 has shown that peripheral blood lymphocytes with a 
phenotype CD45RO+, β1+, which is associated with a T-Helper 1 response, had high 
levels of expression of CXCR3 and CCR5. They went on to show with 
immunohistochemistry that CXCR3 and CCR5+ lymphocytes were present in specimens 
of synovial fluid in rheumatoid arthritis and in ulcerative colitis (118).  Other studies, have 
confirmed CXCR3 and CCR5 expression in rheumatoid arthritis (119), and in other 
inflammatory conditions including multiple sclerosis (120).  More recently, IFN-γ 
producing CCR5+ T-cells have been shown to be present in broncheo-alveolar lavage 
specimens from patients with COPD and airways inflammation (121) (122), liver from 
patients with hepatitis C (123), TIL from renal cell cancers (124), cardiac allograft 
vasculopathy (125) and graft-versus host disease (126).   
 
A study in 2001 has shown by stimulating CXCR6+ peripheral blood lymphocytes then 
performing intracellular cytokine staining, that CXCR6+ cells produced IFN-γ and not IL-
4.  They also went on to show that CXCR6+ T-cells were present in inflamed liver from 
patients with cirrhosis, and synovial fluid from patient with rheumatoid or psoriatic 
arthritis (127).  A study from 2008 suggests that CXCR6 + T-cells are a distinct 
population that are retained within lung tissue that preserve function to keep on producing 
IFN-γ (128). 
 
T-Helper 2 type cells have been shown to be associated with CCR3, CCR4 and CCR8 
(129) (130) (131). It should be noted however, that some chemokines attract polarised T-
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cells from both TH1 and TH2 subsets, for example CCL5 (RANTES) attracts both CCR5+ 
and CCR3+ lymphocytes.  Recently, a study has shown increased levels of CCR3 
expression in ulcerative colitis, but low levels in colonic Crohns disease or normal mucosa 
(132).  
 
 
1.4.7.6 Gut Homing 
In the small intestine, there are discrete lymphoid aggregates, as well as an abundance of 
single immune cells dispersed throughout the epithelium.  Naïve T-cells can enter 
intestinal sites via L-selectin that binds to the ligand mucosal addressin-cell adhesion 
molecule-1 (MAdCAM-1) via its mucin-like region (133) (134).  As with lymph node 
homing, the process can involve interaction between CCR7 and its ligand, resulting in G 
protein activation.  Mature gut homing lymphocytes express the integrin 4β7 that also 
activates MAdCAM-1, via its two immuno-globulin superfamily domains (135) (136). 
 
In the small intestine, most intraepithelial lymphocytes express CCR9 (137), but it has 
been shown that there is also up-regulation of CXCR3 and CCR5 (138).  A study has 
shown that CCR9 expression of lymphocytes from small intestinal mucosa is 
downregulated in Crohns disease, but in normal small intestine 67% of CD3+CD4+ cells 
were CCR9+ compared to 20% of colonic lymphocytes (139).  There are fewer studies in 
the literature concerning T-cell homing to the large intestine.   
1.4.7.7 Homing markers in colorectal cancer 
At the time of undertaking this research, there were no studies in the literature analysing 
the expression of homing markers on colorectal TIL.  Since then, a few small studies have 
been published. Hojo et al found tin 2007 that when CXCL16 is up-regulated in colorectal 
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cancer using immunohistochemistry, there was a higher level of infiltration of CD4+ and 
CD8+ TIL (140).  A study by Musha et al, from Japan (141), has shown using 
immunohistochemistry that colorectal cancer inflammatory infiltrates were localized 
mostly along the invasive margin of the tumour, and that the distribution of CD3 staining 
was similar to CCR5 and CXCR3, although the abundance of CCR5 positive cells was 
greater than CXCR3.  They confirmed their findings using flow cytometry with tumour 
infiltrating lymphocytes, obtained by using collagenases to disaggregate tissue, and 
staining for CCR5 and CXCR3.  They found that 60% of CD8 cells, and 30% of CD4 cells 
co-expressed both receptors.  
 
A recent study using biomolecular network reconstruction (using techniques such as gene 
expression, phenome mapping and tissue micro-arrays) has shown that tumours seemed to 
attract T-cells with a specific TCR repertoire.  The expression of certain chemokines 
(CX3CL1, CXCL10, CXCL9) correlated with high densities of T-cell subsets, and 
consequently disease free survival (142).  A study in 2009 had shown some similar results 
using RNA profiling to analyse chemokine and chemokine receptor expression in eight 
patients.  They also found that and CXCL9 and CXCL10 were expressed, but their 
corresponding receptor CXCR3 was not (143).  In addition, they identified up-regulation 
of CCL4 and CCL5, and CCR1 and CCR5.  
 
In summary, there is a broad range of homing marker receptors, and expression in 
colorectal cancer is not well understood.  Therefore we undertook an analysis expression 
of all the homing marker receptors that had commercially available monoclonal 
antibodies, to assess their expression in colorectal cancer. 
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Investigation of the cell surface phenotype of homing receptor ligands of PBL and TIL 
from patients with CRC is relevant for this study because the expression of homing 
markers may overlap with broad functional differences and this needs to be investigated 
further by separating out T-cells with a particular chemokine receptor and performing 
functional studies.  Subsequently, the levels of expression of particular groups may then be 
used as biological markers of the immunological response at the tumour site. 
 
Analysing the tumour immune response has particular relevance when understanding why 
strategies such as immunotherapy may have a positive impact on eliminating cancer cells, 
or indeed why to date few trials have demonstrated a significant clinical response.  In the 
next section, I outline the principles of immunotherapy, discuss trials conducted in the 
field of colorectal cancer, then consider why analysing the immune response at the tumour 
site may be of use in future trials. 
 
1.4.8 Principles of immunotherapy 
 
Immunotherapy aims to induce anti-tumour immune responses by increasing cancer cell 
immunogenicity or improving the effector cell response.   
 
Active non-specific immunotherapy involves administration of non-specific immune 
modifying infusions, such and IL-2 to activate T-cells or BCG which activates the cell-
mediated response, although the mechanism of action is poorly understood. They may be 
used to augment other passive immunotherapy techniques.   IL-2 and IFN-α infusion have 
been shown to have anti-tumour activity in melanoma and renal cell carcinoma (144) 
(145) (146) (147). 
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Passive immunotherapy involves administration of antibody to tumour-associated antigens 
(TAA), activating the innate response in the form of neutrophilic phagocytosis or Natural 
Killer cell lysis.  Historically, to treat colorectal cancer, there have been extensive trials 
using Murine MAb 17-1A, which targets CD17-1A, a protein present on 90% of CRC 
cells and is involved in epithelial cell adhesion.  A phase III trial of 377 patients that 
targeted cancers which over-expressed this protein did not show any overall benefit (148). 
There have been Phase II trials with antibody 105AD7, which mimics CD55, which 
prevents complement from attacking the cell (149).  CD55 is present in 80% of CRCs.  
Immune responses by peripheral blood lymphocytes to the vaccine antigen were seen in 
most patients.  A previous study by the same group from Nottingham, had shown an 
increase in the percentage of CD25+ TIL in patients who had been given the cancer 
vaccine compared to TIL from patients who were treated with surgery alone (150), but at 
that time CD25+ were thought to include only activated cells and were not known to be 
associated with TREG.  
 
Trovax, an antibody against the colorectal TAA 5-T4, has been studied in a small phase II 
trial of patients with metastatic colorectal cancer (151) (152). It was given alongside 
conventional chemotherapy.  Peripheral blood responses identified 5T4 specific release of 
IFN-γ. There was no evidence of enhanced toxicity in patients receiving this vaccine but 
as yet there have been no phase III trials for colorectal cancer. 
 
Recently monoclonal antibodies which directly alter the immune response have been 
developed.  An example is ipilimumab, an anti-CTLA4 monoclonal antibody used for 
treatment of melanoma.  Blockage of the CTLA-4 receptor on the T-cell membrane 
dampens down inhibition of T-cells, to allow sustained activation thus increasing the 
immune response (153).   A phase III trial of ipilumumab has shown a significant increase 
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in overall survival when given to patients with stage III or IV melanoma (154).  Also of 
interest recently, has been an antibody against PD-1, which has a role in the induction of 
anergy, and blocking this receptor has shown evidence of increased anti-tumour activity in 
patients with solid tumours including colorectal carcinoma (155). In 2009, a study 
involving patients with breast cancer employed the use of Daclizumab, an anti-CD25 
monoclonal antibody that was previously used to prevent rejection in kidney transplant 
patients, prior to immunisation with a tumour antigen vaccine.  The aim is to reduce the 
inhibitory effect of T-regulatory cells (TREG), and they have confirmed the presence of 
Foxp3+ TREG is reduced in peripheral blood, allowing a period of time when it would be 
optimal to administer a cancer antigen peptide vaccine (156).  
 
Adoptive immunotherapy involves in-vitro expansion or activation of live immune system 
effectors, which are then transfused or delivered into the patient, to promote anti-tumour 
responses.  There are two main types of adoptive immunotherapy; T-cell transfer and 
dendritic cell transfer.  Tumour infiltrating lymphocytes (TIL) can be extracted, and those 
expressing tumour associated antigens (TAA)’s selected and enriched, before transfer back 
into the patient.  This involves the targeting of TAA that will be capable of instigating an 
immune response, and should not be one to which the body has already generated a great 
amount of tolerance.  More recent methods involve lymphodepletion of the patient prior to 
transfusion of T-cells, with the aim of removing inhibitory T-cells that might be inducing 
tolerance and dampen the response of infused cells (157).  Amongst the most successful 
studies using these methods have been for melanoma, for example a study from 2005 
involving the treatment of patients who had refractory metastatic disease, and were treated 
with enriched autologous TIL, after lymphodepletion with cyclophosphamide.  The result 
was that there were 3 complete responders and 15 partial responders out of 35 patients, 1 
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year after treatment (158).  There have been many small studies with small numbers of 
responders, but reviews have shown the overall response rates to be low (159). 
 
Adoptive immunotherapy involving dendritic cell transfer has also been extensively 
investigated.  These methods involve harvesting DC’s from a patient, expanding their 
numbers and pulsing them with a TAA, so that when they are transferred back into the 
patient they will activate T-cells with the aim of producing an anti-tumour response.  
Recently, a DC based immunotherapy for metastatic hormone resistant prostate cancer has 
been licensed for use in the U.S. after results from a phase III trial had shown a 4.1 month 
median improved survival (39). 
 
Adoptive immunotherapy has been attempted to treat colorectal cancer using both 
dendritic cells and T-cells.  Pre-clinical studies have given hope that a positive anti-tumour 
response can be induced in vitro.  As yet no study has demonstrated a clinically useful 
overall improvement in disease-free survival in the clinical setting, but there are some 
individual stories of success.   
 
Several studies in which DC have been pulsed with CRC cell lines or peptides can result 
in proliferation of activated lymphocytes in vitro (160) (161).  A recent Phase II trial 
involving 17 patients with metastatic disease, used DC’s pulsed with autologous tumour 
cell lysate, and demonstrated an increase in serum levels of (anti-tumour) T-Helper type-1 
cytokines in patients who had stable disease, which was achieved in 24% of cases (162).  
A study by Fong et al studied the treatment of advanced cancer patients with Flt3 ligand, a 
haematopoietic growth factor used to expand DC numbers in the blood stream.  Dendritic 
Cells were then extracted and loaded with antigen, and the patient then vaccinated.  CD8 
cytotoxic T lymphocytes that recognized tumour cells expressing endogenous CEA were 
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then found to be present in the blood stream of these patients.  After vaccination, 2 of 
twelve patients had dramatic tumour regression.  A study by Gardini et al (163) involved 
obtaining TIL from surgical specimens, activating with IL-2 and subsequently re-infusing 
activated autologous T-cells.  Prior to activation, the TIL obtained were found to be 
immuno-depressed with alterations in the T-cell Receptor.  Following induction with IL-2 
there was restoration of the TCR.  Although there was no overall change in disease free 
survival, there was a suggestion of a reduced risk of recurrence in patients who had a high 
level of restored TCR formation.  This highlights the need to look at the immune response 
in detail with such studies, in order to elucidate the effect on the tumour 
microenvironment, rather than rely on crude measurements such as disease-free survival 
statistics. 
 
Analysing the immune response at the tumour site in all of these types of trial would 
provide detailed evidence of whether any of these immunotherapeutic techniques were 
altering the immune response. It would also demonstrate whether the type of response 
contained activated cells capable of cancer cell elimination, or, anergic/suppressive cells 
that dampen down the response.  This is important given the lack of success of 
immunotherapy trials in colorectal cancer to date. 
 
1.4.9 Measuring Outcomes in Colorectal Cancer Immunotherapy Trials 
 
To assess outcome, most previous studies have often relied on using crude assessments 
such as carcino-embrionic tumour antigen measurement and radiological assessment of 
metastases (134), imaging of radionuclide labelled CEA (164), skin testing (165) and 5-
year survival statistics.  Some studies have attempted to measure the effect on lymphocyte 
response after vaccine therapy, by testing the response of peripheral blood lymphocytes to 
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vaccine associated antigens, for example by proliferation assay in response to antigen, or, 
by a delayed-type hypersensitivity skin reaction (166) (167) (149).   
 
When considering neo-adjuvant immunotherapy, there is an excellent opportunity to 
harvest tumour biopsies once the intervention has taken place, to assess and measure the 
effect of tumour vaccines on the immune response at the site of the tumour.  Phase 1 trials 
aim to determine the proof of principle of a therapy, and for that, biomarkers of the 
immune response would serve as suitable end-points.  A previous neo-adjuvant trial was 
performed within the department using a K-Ras vaccine (168).  Patients were vaccinated 
prior to surgery and then evidence of a specific immune response was investigated by skin 
testing and IFN-γ release from blood and tumour lymphocytes. This trial provided the 
impetus to look further into the tumour immune environment of this disease, and also to 
understand more fully which methods may be used to monitor the possible effects of a 
vaccine and which immunological factors may be useful ‘biomarkers’ of the immune 
response.   
 
In summary, we should analyse the CD4+ T-cells in colorectal cancer because T-cells are 
responsible for the adaptive immune response that immunotherapeutic therapies aim to 
augment. They are the most abundant type of lymphocytes present in colorectal cancer and 
we know that CD4-Helper cells are required to produce a maximal CD8 cytotoxic effect. 
However, different sub-types of CD4+ cells exist with opposing functions (enhancing 
versus damping down the immune response).  Neo-adjuvant and window trials both give 
us the opportunity to harvest tumour after a therapy has been initiated, and all types of 
treatment including chemotherapy or molecularly targeted therapy may have an effect on 
this local immune response.  The work carried out was intended to ascertain how we could 
analyse the local immune response with the aim of it being in a reproducible way so that it 
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could be used as part of future trials, and at the same time investigate the subtypes of T-
cells present in colorectal cancer and analyse the functional capabilities of those TIL. 
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1.5 Aims of Research 
 
 
The context of this project is that both conventional and novel biological CRC treatments 
can have immuno-modulatory effects on tumour deposits as well as direct effects on 
malignant cells.  An understanding of immune interactions within CRC might lead to the 
development of modalities such as vaccination, and in addition, the specific rationalisation 
of treatments for individual patient care.  The focus of the project is on the most dominant 
lymphocyte population, CD4+ T-cells.  Characterising the phenotypic and functional 
properties of CD4+ T-cells in the primary tumour might serve as a biomarker for the 
immune effect of treatments given before surgery, for example in window trials. 
 
The objectives were: 
(i)  To test the hypothesis that the CD4+ population in colorectal cancer is 
heterogeneous including various different functional sub-types such as those with 
helper or regulatory functions 
(ii) To test the hypothesis that CD4+ cells in colorectal cancer are heterogeneous in the 
expression of molecular homing markers 
(iii) To investigate whether cell surface receptor profiles associate with functional 
differences, potentially leading to immune profiling of tumours for use in the 
research setting 
 
This project potentially represents the early stages in biomarker discovery and 
development and therefore there were some key technical aims: 
(i) validate a tissue harvesting protocol 
(ii) validate the use of flow cytometry for characterising phenotypic profiles in TIL 
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(iii) validate assays measuring TIL function after stimulation  
(iv) identify methods of separating a TIL population into subgroups depending on a 
specific cell surface marker coupled with analysis of function 
 
The aim was that paired samples of peripheral blood, tumour and local lymph node would 
be harvested from each patient.  Only fresh, live TIL could be used for these types of 
assays.  
 
Regarding the harvesting of tissue, the aim was to assess the optimal conditions in which 
to harvest tissue, transport it, separate the lymphocyte fraction and prepare them for flow 
cytometry.  I would assess mechanical disaggregation to determine whether it is possible 
to obtain useful quantities of TIL. As the number of live TIL obtained would limit the 
number of assays that could be performed, so sets of experiments would be performed on 
small cohorts of sequential patients. 
 
To determine the presence of Regulatory T-cells in colorectal cancer, I would perform 
flow cytometry to assess the expression of CD25HIGH.  During the period of research 
antibodies for immunohistochemistry for FoxP3 expression became available so this was 
performed on paired tumour samples (to those analysed for CD25 expression). 
 
The overall pattern of expression of homing factors on tumour infiltrating lymphocytes or 
normal mucosa was not known.  In order to identify which markers may be of interest, I 
would look at the expression of a broad range of homing markers present on tumour 
infiltrating lymphocytes in colorectal cancer, and compare this with lymphocytes found in 
peripheral blood, normal mucosa and local lymph nodes using flow cytometry.  
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I would aim to measure the function of the whole TIL population and compare it with PBL 
and LNL.  I would stimulate TIL then use well known assays such as ELISA or Elispot to 
measure cytokine response. It is not necessarily the case that research methods which 
work with PBL can be used for TIL without modification, and I wished to address this 
issue as part of the study.  Interferon-γ is the most widely measured cytokine as it indicates 
a Type1, anti-tumour response. The aim was to measure IFN-γ release from TIL primarily 
but, to extend this to IL-10, TGF-beta and IL-4. It was anticipated that the methods used to 
measure release of these cytokines would evolve with sequential patients recruited. 
 
In this era, where we need improved treatment for colorectal cancer, we also need methods 
to assess and predict the response to therapy in a timely fashion so that treatment can be 
tailored to the patient.  This study is valuable because of the recent renewal in interest in 
neo-adjuvant immunotherapy or ‘window trials’ for colorectal cancer, where patients 
undergo systemic treatment prior to surgery. After neoadjuvant therapy there is the 
opportunity to harvest lymphocytes from the tumour site. In 2009, a task force was set up 
by the USA food and Drug administration and The International Society for the Biological 
Therapy of Cancer with the primary goal of identifying emerging immunological concepts 
that could predict responsiveness to immunotherapy and/or explain its mechanisms (169). 
Currently, there are no standard methods to monitor the effects on the local tumour 
immune response after an intervention to treat colorectal cancer has taken place. The 
anticipated outcome of this study would be to have a set of immunological ‘biomarkers’ 
which could be used to assess the effect of future neo-adjuvant immunotherapy trials. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Clinical Material 
 
All materials used were obtained from patients undergoing surgery for colorectal 
carcinoma at University Hospital Birmingham NHS Trust, or from normal donors from the 
Institute for Cancer Studies at Birmingham University.  Ethical approval was obtained 
prior to the study from the North Birmingham Local Research and Ethics Committee.  
(REC reference no 857.04) Patients with confirmed colorectal cancer were identified.   
 
The Human Tissue Act of 2004 was published just as this study began. Good practice was 
adhered to, consisting of informed consent being obtained in advance of the day of 
surgery, the use of patient information leaflets and study specific consent forms, 
anonimisation of specimens with a unique identifying number, and, as stated on the 
application to the Regional Ethics Committee, specimens not used immediately were 
stored anonymously using the unique identifying number. Records of the stored specimens 
were maintained in a secure way by the principle investigator.   
 
2.1.2 Buffers, media and solutions 
 
Blocking Buffer, 1% BSA/PBS filtered and then Tween added (50μl/100ml) 
Coating Buffer, 0.1M Na2HPO4, adjusted to pH9 with 0.1M Na2HPO4 
Colonic Antibody Cocktail Culture Medium, RPMI 1640 500ml, 8% FCS, Vancomycin 
10mg/ml 500μl, amoxicillin 222mg/ml 800μl, gentamicin 40mg/ml 3125μl, metronidazole 
5mg/ml 800μl, fungizone 2.5ml stock solution, glutamine 10ml. 
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Culture Medium; RPMI 1640 + L-Glutamine (Invitrogen, UK), 10% Fetal Bovine Serum 
(Invitrogen), 2mmol Glutamine (Sigma-Aldrich, UK), 100IU/mL Penicillin (Sigma-
Aldrich,UK), 100 μg/mL streptomycin (Sigma-Aldrich UK) 
FACS Buffer; Phosphate-buffered saline (Sigma) pH 7.4 and 2% fetal calf serum 
MACS Buffer 
Stopping Buffer, 1M Phosphoric acid or ¼ dilustion of stock H2SO4 
TBS; Tris buffered saline pH 7.6 TBS/ Tween; 500ml TBS and 500μl Tween 
Wash Buffer, PBS/0.05% Tween 
2.2 Methods 
 
Patients were identified in the multi-disciplinary team meeting prior to entering the 
clinical study pathway.   An overview of patient pathway, harvesting of specimens and 
laboratory pathway can be seen in Figure 2.1. All of the assays performed required the use 
of fresh live TIL and as a result the experiments undertaken could not be performed in 
batches, but had to be done separately at different time points.  One set of PBL, TIL and 
LNL could be harvested per week, when a patient presented for surgery with colorectal 
cancer.  Once lymphocytes were harvested, they were prepared for both flow cytometry 
and cell culture the same day.  The following day flow cytometry was performed. Once 
the lymphocyte cultures had been stimulated for 24 – 48 hours, functional assays could be 
undertaken.   
 
The aim was that paired samples of blood, tumour and lymph node were collected from 
each patient. Patients with small tumours or patients with rectal cancer who had a good 
result from radiotherapy had blood collected but the residual tumour was left intact 
because these tumours were generally too small to harvest tumour without compromising 
histological analysis and staging.   When analysing homing marker expression we began 
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harvesting normal mucosa because the expression of these markers in the colon was 
largely unknown.  For each set of experiments, PBL were harvested from a lab donor as a 
control for the experimental method (ie not a paired control for the actual result but to 
ensure the assay was working). 
 
2.2.1 Tissue Harvesting 
2.2.1.1 Preparation and cryopreservation of serum samples 
A 7ml non-heparinised blood sample was taken prior to surgery.  In order to prevent 
proteolysis, the specimen was placed on ice immediately, and was processed within 4 
hours.  All specimens were allowed to thaw for 30 minutes at room temperature prior to 
processing.  The whole blood specimen was then centrifuged at 1000g for 10 minutes 
(HETTICH ROTINA 46R), the serum supernatant was obtained by aspiration, then, 
centrifuged for a further 2 minutes at 1000g.  Serum was aliquoted and cryo-preserved at -
80 oC. 
2.2.1.2 Isolation of peripheral blood lymphocytes from whole blood 
Heparinised venous blood was taken from healthy adults and patients (monoparin 1000 
IU/ml CD pharmaceuticals).  This was diluted 1:1 with culture medium warmed to 37˚C 
and layered on 15mls of lymphoprep gradient (Fresenius Kabi Norge AS), followed by 
centrifugation at 400g, at room temperature, with the brake off.  The mononuclear cell 
layer was extracted by aspiration with a transfer pipette, and re suspended in 20mls culture 
medium.  Further centrifugation at 280g for 10 minutes, followed by repeated washes and 
centrifugation for 5 minutes at 180 and 110g was performed. 
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2.2.1.3 Collection of Tumour, Lymph node and Mucosal samples 
Tumour samples were obtained immediately after the colonic resection specimen was 
removed from the patient (Fig 2.2).   
 
 
The sample was excised from the rolled edge of the tumour.  In agreement with the 
pathologist and ethics committee, up to 20% of the tumour mass could be excised for 
research purposes.  The mesentery was inspected by bimanual palpation to identify the 
nearest palpable lymph node.  This lymph node was subsequently excised and divided into 
two.  Half of the lymph node was taken for research, and half sent to the histopathology 
lab to allow accurate staging of the tumour.  In the experiments that involved the use of 
mucosal infiltrating lymphocytes, 1g of mucosa was excised from the proximal end of the 
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specimen, at least 10cm from the site of the tumour.  All specimens were placed in 
separate universal containers with colonic antibiotic cocktail culture media prior to 
transfer back to the laboratory.  Where possible, further tumour and mucosal samples of 
roughly 0.2g were placed in Nunc CryoTube Vials (Nalge Nunc International, Denmark) 
pieces, then snap frozen frozen in liquid Nitrogen prior to storage at –80˚C. 
 
The remaining specimen was sent to the pathology lab in formalin and analysed as per the 
usual protocol.    
 
2.2.1.4 Isolation of TIL, LNL and MIL 
Tissue disaggregation was performed mechanically using a Medimachine 
(DakoCytomation, Denmark AS) (Fig. 2.3).  Enzymatic degradation was not considered as 
this process can alter the surface phenotyping of cells (170) .   
 
After weighing the specimens, they were divided into fragments of roughly 0.2g.  Sterile 
50 μm medicons ( DakoCytomation Denmark AS) were prepared with culture medium 
then loaded with tumour fragments.  Disaggregation was performed in 45-second cycles, 
and then the cell suspension was aspirated into a sterile 5ml syringe.   Sterile 100μm cup 
filcons (DakoCytomation Denmark AS) were prepared with culture medium, and then the 
cell suspension was filtered.  Separate medicon-filter systems were used for each tissue 
type being prepared.  Between cycles, the medicon was washed with 3ml culture medium, 
and this was also filtered for maximal retrieval of cells.  The whole process was repeated 
up to ten times.   
75 
 
 
2.2.2 Cell Preparation for Flow Cytometry 
 
Negative controls 
Unstained cells and isotype controls were used for every antibody in every tissue tested to 
confirm that primary antibody testing was specific and not a result of non-specific binding 
to antibody or other proteins.  
 
Positive controls 
As fresh samples were used for the flow cytometry experiments, each set of paired 
samples were analysed at a different time point.  As there is normally a population of 
CD3, CD4 and CD25 found in healthy states, PBL obtained from lab donors were used as 
a control each time.  For the panel of 18 homing markers tested separate positive controls 
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were not used because of difficulty in obtaining tissues in which separate markers are 
known to be raised in either disease or health. 
 
Flow cytometry preparation 
2.5x105 cells suspended in culture medium were transferred to each standard flow 
cytometry tube.  They were washed twice (PBS/2% FCS) after centrifugation at 180g.  
After pelleting the cells, the supernatant was poured off, and antibody stains were added in 
pre-determined concentrations to give a final volume of 50 μl.  Samples were incubated on 
ice for 30minutes.  To wash the samples, 4ml of PBS/2% FCS was added, and then 
samples underwent centrifugation at 180g for 5 minutes.  Cells were re-suspended in 
500μl PBS/2% FCS if proceeding to flow cytometry straight away, or in PBS/2% FCS/2% 
paraformaldehyde if storing cells overnight.  Cells were stored at 4˚C in the dark.  Flow 
cytometry was performed on a Coulter Epics XL-MCL flow cytometer (Beckman 
Coulter). Analysis was performed using WinMDI 2.8 (Joseph Trotter). 
 
For CD3+ staining we used FITC-conjugated mouse anti-human IgG1 clone UCHT1 from 
BD Pharmingen, for CD4 FITC-conjugated mouse anti-human monoclonal antibody (BD 
Pharmingen), and for CD25 PE-conjugated mouse anti-human IgG2a clone B1.49.9 
(Beckman Coulter).   Corresponding IgG1 and IgG2a isotype controls were also used. 
 
In the first of two groups of experiments looking at homing marker expression, samples of 
blood, tumour, lymph node and mucosa were analysed using 3-colour flow cytometry to 
assess staining on CD3+ and CD4+ lymphocytes.  In the second group of experiments, we 
concentrated on a smaller panel of antibodies, which appeared to be of interest, and used 
4-colour flow cytometry to assess binding on both naïve and memory T-cells. 
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Cells were labelled with a panel of 18 unlabelled antibodies to homing and adhesion 
markers, including, CCR1 (clone 53504.111), CCR2 (48607.121), CCR3 (61828.111), 
CCR6 (53103.111), CXCR4 (44716.111), CXCR5 (51505.111), CXCR6 (56811.111) 
(R&D systems UK); CCR4 (1G1), CCR5 (2D7), CCR7 (3D12), CXCR3 (1C6) 
(Pharmingen, UK), LFA-1 (HI111), PSGL-1 (KPL-1), CLA (HECA-452) (Pharmingen) 
and VLA-4 (P4G9) (Abcam). Isotype controls were used in all cases. Cells were then 
washed in buffer and stained with biotinylated anti-mouse or anti-rat IgG.  Streptavidin 
Alexa 488 was added.  As a blocking step, cells were then washed and incubated with 
normal mouse serum, before being stained with both mouse antihuman-CD3 (PC5) and 
mouse antihuman CD4 (PE) (Coulter, UK).  Three-colour flow cytometry was performed 
on an Epics XL Flow Cytometer (Beckman Coulter).   
 
In the second group of homing marker experiments, the same methods were used to 
investigate expression of receptors including CXCR3, CXCR5, CXCR6, CCR5 and 
CCR6, as these were the receptors that looked to be of interest after the first set of 
experiments had been completed.  In addition, the presence of memory versus naïve T-
cells, was assessed by staining for CD45RA, as a marker for naïve cells.  Cells were 
labelled using CD3-PC5 anti-human monoclonal, CD4-PE anti-human monoclonal 
antibody and CD45RA-ECD anti-human monoclonal antibody.  Analysis was performed 
using 4-colour flow cytometry. 
 
2.2.3 Method of validation of cell numbers obtained from tissue harvesting 
 
10μl cell suspension was added to 10μl Trypan blue solution 0.4% (Sigma-Aldrich, UK) 
and cell numbers were estimated by counting with a haemocytometer.  Cells were then 
prepared for flow cytometry, with an estimated final concentration of 5x105 cells/ml.  The 
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flow cytometer was set to count the total number of cells present in 20μl of cell suspension 
in triplicate.  By gating on the lymphocyte population, it was possible to count the total 
number of cells present, the percentage of CD3+, and of CD4+ cells present.  This data 
was used to confirm the actual cell numbers present in the ELISA experiments that 
followed. 
 
2.2.4 Lymphocyte stimulation 
 
Lymphocytes were stimulated by the addition of either soluble or plate-bound substrates.  
The soluble peptides used included PHA (final concentration 1μg/ml, diluted in PBS), 
OKT3 (final concentration 30ng/ml, diluted in PBS), and EBV peptides (final 
concentration 10μg/ml diluted in PBS).  Anti-CD3 and anti-CD28 antibodies (BD 
biosciences Pharmingen) were plastic bound the day before cell harvesting by coating 96-
well U-bottomed plates with the antibodies diluted in PBS at 1μg/ml.  The plates were 
covered and stored at 4˚C overnight.  Following stimulation, cell cultures were incubated 
at 37oC/5%CO2. 
  
2.2.5 ELISA for interferon gamma 
 
The Enzyme Linked Immuno-Sorbant Assay (ELISA)  method involved, firstly, coating of 
a nunc maxisorp 96-well plate with capture antibody (Pierce Endogen) to recognise the 
cytokine to be measured.  The capture antibody was diluted in coating buffer to a 
concentration of 0.75μg/ml.  The plate was sealed with nescofilm and stored overnight at 
4oC in the dark.  
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The following day, 2 hours before the supernatant was to be harvested, blocking buffer 
was added, 200μl/well.  The cell culture plate and the maxisorp plate were both 
centrifuged at 400g for 3 minutes.  The blocking buffer was removed with wash buffer and 
a plate washer (Ultrawash plus, Thermo Lab systems).  Supernatant from the cell culture is 
then added 50μl/well.  All assays were performed in triplicate and PBL from lab donors 
acted as controls. Standard preparations of recombinant human interferon gamma were 
prepared with 2-fold dilutions from 2000pg/ml to 31.25pg/ml, and again 50μl/ well added 
to the maxisorp plate.  The samples were incubated for 2-4 hours at room temperature.  
Following this, the plate was washed four times.  A biotin bound detection antibody that 
binds a different epitope of the cytokine is then added.  50μl/well of interferon-γ 
biotinylated Mab (Pierce Endogen) was used at a concentration of 1.5 μg/ml.  The plates 
were incubated for 1 hour at room temperature, then washed 4 times.  Extra-avidin 
Peroxidase conjugate (Sigma), which binds to biotin, was diluted 1/1000 with blocking 
buffer and 50μl/well added.  The plates were incubated for 30 minutes at room 
temperature, then washed 8 times.  90ul/well TMB supersensitive substrate (Tebu-bio 
laboratories), which reacts with Extra-avidin to cause a colour change, was added.  The 
colour was allowed to develop for 20 minutes and the reaction ended with stopping buffer.  
The absorbance of the colour produced was read on a plate reader (Victor2 1420 
Multilabel counter, Wallace). 
 
2.2.6 ELISPoT for interferon gamma  
 
An ELISPoT plate was prepared by adding 50l of 70% ethanol in sterile distilled water 
per well.  This was incubated at room temperature for 2 minutes.  The plate was flicked to 
remove the solution and the plate washed with PBS.  Coating antibody, Anti-Human 
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Interferon- mAb clone 1-D1K (MABTECH), was diluted to 7.5g/ml and 50l was then 
added to each well.  This was left overnight at 4oC.  The following day, the plate was 
flicked and washed with PBS.  Each well was then blocked for 1 hour with culture 
medium.  The cell culture was then added at 80l/well.  Again, every assay was performed 
in triplicate, PBL from lab donors acted as positive controls, and culture medium with no 
cells acted as negative control.  OKT3 at a concentration of 20l/well was added.  This 
was incubated overnight at 37 oC/5%CO2.  The secondary antibody, detection Anti- 
interferon- biotinylated MAb clone 7-B6-biotin (MABTECH) was added and incubated 
at room temperature for 2-4 hours.  Streptavidin-alkaline phosphatase was then diluted to 
1:1000 in PBS.  The plate was washed and then Streptavidin added at 50 l/well.  This 
was incubated at room temperature for 1.5 hours.  The plate was then washed , and the 
backing plate removed.  It was rinsed by dipping in a tray of Tween/ PBS.  100l of 
Chromagens A and B were added to each well and mixed.  Substrate was added at 
100l/well and left for one hour before rinsing the plate. Spots were counted using an 
automated counter. 
 
 
2.2.7 Intracellular Cytokine Staining for interferon- 
 
Following a Ficoll separation, lymphocytes were split into group A (un-stimulated) and 
group B (stimulated).  PHA was added (1g/ml) to group B and incubated at 37oC for 6-
16hours.  Brefeldin A (10g/ml) was added for the last 2 hours.  The samples were 
washed and then 5x105 cells dispensed to each tube.  20L of membrane isotypic control 
was added to each control tube, and 20L of membrane specific conjugated monoclonal 
antibody (eg. Anti-CD4 PE to the rest.  Tubes were incubated for 15 minutes at room temp 
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then 100l of intraprep reagent 1 to each tube.  Following a further incubation of 15 mins 
we added 4 ml PBS, and tubes centrifuged for 5 mins at 300g.  Supernatant was discarded 
by aspiration and 100L of intraprep reagent 2 added.  This was incubated for 5 minutes 
then gently agitated for 1-2 seconds.  20L of intracellular conjugated specific antibody or 
control was added, vortexed, and incubated for 15 mins.  4ml of PBS was added and 
centrifuged for 5 mins at 300g.  Cells were re-suspended in 500L of PBS containing 
0.5% formaldehyde and flow cytometry analysis performed. 
2.2.8 ELISA for interleukin – 10 
 
ELISA for interleukin-10 was performed according to the protocol for interferon-γ.  
Coating antibody (Pierce Endogen) was used at a concentration of 2μg/ml, and detection 
antibody (Pierce Endogen) at 1.5μg/ml. 
 
2.2.9 ELISA for transforming growth factor beta 
 
ELISA for TGF-beta was performed using the Duoset development system (R&D 
systems).  The assay procedure involved an extra acid activation step of the culture 
supernatant, but otherwise was the same as for interferon-γ ELISA.  The acid activation 
step was required to activate latent TGF-β1.  0.1ml 1 N HCl was added per 0.5ml sample.  
This was incubated at room temperature for 10 minutes, and then neutralised by adding 
0.1ml 1.2 N NaOH/0.5 M Hepes per 0.5ml sample.  In initial assays using culture medium 
containing fetal bovine serum, significant background levels of TGF-β were found.  The 
assay was repeated with serum free media, AIM V (Gibco, Invitrogen Corporation). 
 
82 
 
2.2.10 ELISA for interleukin-4 
 
ELISA for interleukin-4 was performed using the Duoset development system (R&D 
systems).  This technique was first validated using PBL from a healthy donor.  Cells were 
stimulated for 48 hours with OKT3 at 37oC/5%CO2.  As is expected, in vitro levels of IL-4 
produced were very low, and difficult to detect.  It is thought that the IL-4 produced is 
readily consumed by contaminating red blood cells that have IL-4 receptors on their cell 
membranes.  The assay was repeated in the presence of IL-4 receptor antibody (R&D 
systems) in order to block the consumption of the IL-4 produced by T-cells.  PBL and 
LNL were obtained from a patient, and incubated for 38 hours at 37oC/5%CO2, with and 
without the presence of OKT3.  IL-4 receptor blocking antibody was added at varying 
concentrations.  An increase in the amount of IL-4 detected from PBL in the presence of 
IL4 receptor blocking antibody was seen. 
 
2.2.11 Immunomagnetic separation for depletion of CD25+ cells  
 
PBL are first obtained from a heparinised blood sample by ficoll separation and 
differential centrifugation.  Cells are pelleted by centrifugation at 400g, then re-suspended 
in cold MACS buffer.  The cell suspension is then passed through a 30μm mesh, and a cell 
count is performed.  Cells are again pelleted by centrifugation at 400g, and then re-
suspended to a total volume of 100μl.  10μl of CD25 microbeads  (Miltenyi biotech) are 
added allowed to incubate for 15minutes at 4oC.  Cells are then washed in 2ml MACS 
buffer and centrifuged at 300g for 10minutes.  The supernatant is removed by aspiration, 
and cells re-suspended in 500μl MACS buffer.  The MACS LD column (Miltenyi Biotech) 
is placed in a magnetic field, and the column prepared with 3ml MACS buffer.  The cell 
suspension is applied to the column and unlabelled cells are collected.  The column is 
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washed with 3ml MACS buffer three times, and the total effluent collected.  The column is 
removed from the vicinity of the magnet, and 5ml MACS buffer applied.  This is 
immediately flushed out by firmly applying the plunger to the column, and the 
magnetically labelled cells can be collected. 
 
2.2.12 Agitated Low Temperature Epitope Retrieval Immunostaining Technique 
(ALTER)  
 
This technique has been developed within the department to allow immunohistochemical 
staining of paraffin embedded sections [46].  Sections of paraffin embedded tissue are 
prepared onto slides.  Sections are first deparaffinised in xylene for 5 minutes, and then 
into industrial methylated spirits for 5 minutes.  They are then washed in water.  In order 
to block endogenous peroxidises (that might otherwise cause non-specific colour change 
in the chromagens used at the end of the procedure), and also to prevent breakdown of 
tissue, they are then placed in 0.3% hydrogen peroxide for 15 minutes, then, again 
washed in water.  Sections are placed into EDTA/Tween Buffer overnight at 65oC with a 
stirrer set at 600rpm. 
 
2.2.13 Immunohistochemistry with FOXP3 antibody 
 
The following day, sections are washed under tap water to bring back to room 
temperature, then washed in TBS.  Slides were then blocked with 10% sheep serum for 10 
minutes to prevent non-specific binding by the primary antibody.  The primary antibody is 
applied at the optimal dilution for 1 hour.  For foxp3 staining we used anti-human Foxp3 
goat polyclonal antibody (Abcam) diluted 1/200 in TBS. Controls with IgG1 isotype 
antibody rather that the primary antibody were performed in every case. Tissue type 
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controls for positive of negative staining were not used, although they would have been a 
useful reference if available. Human tonsil is now known to act as a positive control. 
 
Slides are washed in TBS/Tween, then a secondary antibody, rabbit antigoat monoclonal 
antibody (DAKO) is added at a 1/100 dilution in TBS.  This is incubated for 30 minutes, 
then washed in TBS/Tween.  DakoChemate Envision secondary is applied to each slide 
for 30minutes, then removed by washing with TBS/Tween. Staining is visualised with 
DAB chromagen, which is applied for 5 minutes and then washed in water.  The slides are 
counterstained with haematoxylin for one minute, and then washed in warm water.  The 
slides are placed in industrial methylated spirits followed by xylene prior to mounting in 
DPX. 
 
2.2.14 Flow assisted Cell Sorting of CD4+CXCR6+ T-Lymphocytes 
 
Lymphocytes were stained with mouse anti-human CXCR6 clone 56811.111 (R&D 
systems UK) and the corresponding isotype control.  Biotinylated secondary antibody was 
added followed by streptavidin.  After a blocking step, cells were stained with mouse 
antihuman-CD3 (PC5) and mouse antihuman CD4 (PE) (Coulter, UK). 
 
In house sterile flow assisted cell sorting was available at the institute for cancer studies.  
CD4+CXCR6+ and CD4+CXCR6- TIL populations were obtained.  Samples were split to 
those which were stimulated by plate bound CD3/CD28 MAb (section 2.2.4), and those 
left un-stimulated.  Cells were incubated at 37oC/5%CO2 for twenty-four hours. 
 
After centrifugation at 1700rpm, supernatant was harvested and IFN- ELISA performed 
(section 2.2.5).  
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3 Patients and Samples 
 
At the start of this study (which is aiming to identify phenotypic and functional 
immunological biomarkers that could be used to assess the immune response in colorectal 
cancer), there were no ‘collections’ of samples available for retrospective immunological 
studies, no standard operating procedures in place for the collection of samples, and no 
standard assays defined that could be used for TIL analysis.  Basic research was required 
to ensure that it was possible to harvest a live lymphocyte population and analyse it with 
flow cytometry in an accurate and reproducible manner, both of which are important steps 
in biomarker discovery (see section 1.3.1 and the Biomarker Roadmap appendix 8.1).  
3.1 Tissue Samples  
 
All patients with colorectal cancer presenting to a single surgeon were invited to take part 
in the study.  Specimens were obtained from patients that agreed to take part.  The samples 
from small cohorts were used for small groups of experiments, in the order that they 
presented for surgery.  There was no bias towards a certain stage or grade of tumour.  
However, TIL were not harvested if the tumour was too small as this would have 
compromised accurate staging, or, if a very low yield of lymphocytes were obtained 
functional studies could not be undertaken, both of which could introduce some degree of 
bias into the study. 
 
The aim was to collect paired blood, tumour and local lymph node lymphocytes from each 
patient, although this did change as the study progressed.  Blood was collected 
immediately prior to surgery (in the anaesthetic room) and PBL extracted (section 2.2.1.2).  
Once the specimen was resected, tumour specimens were taken and lymph node was 
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identified by bimanual palpation of the mesentery (section 2.2.1.3).  Tumour and lymph 
node biopsies then underwent mechanical disaggregation (see section 2.2.1.4). 
 
Blood was obtained from 38 consecutive patients and tumour from 35 patients. In four 
patients the tumour was too small to harvest from the outset. These patients had undergone 
pre-operative radiotherapy for rectal cancer. In three instances there was no attempt to 
harvest TIL.  This was when attempting a new procedure such as MACS there was an 
effort to first validate the assay using PBL prior to using TIL.   
 
Lymph node was harvested from 26 patients.  In some cases, lymph node was not easy to 
identify. Care was taken to prevent damage to the specimen that could compromise 
subsequent lymph node analysis by the pathologist. In 4 cases where lymph node was 
thought to be harvested, viable lymphocytes were not obtained.  This was not discovered 
until the rest of the resection specimen was fixed in formalin and the TIL and LNL 
samples taken for research purposes were mechanically disaggregated and inspected with 
light microscope.  If tumour could not be harvested, there was no attempt to harvest lymph 
node or undertake the functional studies, but the phenotyping of the PBL that had already 
been obtained prior to the commencement of surgery was still performed.  With the cohort 
of patients’ samples that were used to study homing marker expression in memory T-cells, 
I did not attempt to characterise homing markers in lymph nodes as this was already well 
documented in the literature (section 1.4.7.3), therefore further analysis of LNL would not 
contribute to our knowledge.  Instead I wished to concentrate on whether there was 
selective uptake of lymphocytes both into CRC and normal colonic mucosa as this was not 
previously well documented (section 1.4.7.6). 
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The sample groups were small, as the assays undertaken had to be performed on one 
patient at a time, as they presented for surgery.  Only live TIL could be used as 
cryopreservation of samples could alter cell surface receptors. It would therefore take 
several weeks to perform one group of experiments.  The number of TIL harvested proved 
to be the limiting factor on the number experiments performed; there would generally be 
enough TIL to perform one phenotypic and one functional analysis on the samples from 
each patient.  All available TIL were used up in the assays undertaken; assays could not be 
replicated or extended if results were not obtained.  I accept that each cohort is 
heterogeneous and opportunistic in that I had to accept each patient as they presented for 
surgery, and did not standardise for factors such as tumour site or histological grade. The 
small sample size and heterogeneity of the cohort must be taken into account during the 
analysis and is discussed in section 6.   
 
 
3.2 Patients 
 
 
No 
 
Age 
 
Gender 
 
Histology and 
stage 
 
Left 
versus 
right 
 
Specimens taken 
 
Experimental aim 
1 73 F Adenocarcinoma 
T2N0 
 
L PBMC, TIL, LNL 
TIL: good staining on 
CD3 / CD4 only  
not enough cells in 
CD4/CD25 sample 
Analysis of CD4 cell 
surface phenotype 
2 68 M Adenocarcinoma 
T1N0 
L PBMC 
Tumour too small 
(radiotherapy) 
 
Analysis of CD4 cell 
surface phenotype 
3 77 M Adenocarcinoma
T3N1M1 
 
L PBMC, TIL, LNL Analysis of CD4 cell 
surface phenotype 
4 83 F Adenocarcinoma L PBMC, TIL Analysis of CD4 cell 
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T2N0 Attempted LNL- no 
viable lymphocytes after 
disaggregation 
 
surface phenotype 
5 71 M Adenocarcinoma
T4N2 
R PBMC, TIL, LNL Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
6 77 M Adenocarcinoma
T3N0 
L PBMC, TIL, LNL Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
7 84 F Adenocarcinoma 
 
L PBMC 
tumour too small 
 
Analysis of CD4 cell 
surface phenotype 
8 79 M Adenocarcinoma
T4N2 
R PBMC, TIL 
LNL not obtained on 
disaggregation 
No stain uptake with TIL 
for CD3 or CD4 
Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
9 64 M Adenocarcinoma 
T3N0 
L PBMC 
Tumour too small 
 
Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
10 54 F Adenocarcinoma
T2N0 
L PBMC,  
Tumour was harvested, 
but there were not enough 
viable TIL seen on flow 
cytometry. No data for 
LNL  
 
Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
11 64 F Adenocarcinoma
T3N1 
L PBMC, TIL, LNL Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
12 73 M Adenocarcinoma
T1N0 
L PBMC, TIL, LNL 
TIL CD3/CD4 population 
obtained 
No viable CD4/CD25 
population 
Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
13 61 M Adenocarcinoma 
Poorly 
differentiated 
signet ring type 
L PBMC 
No viable LNL or TIL 
seen on flow cytometry. 
 
Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
14 66 F Adenocarcinoma
T1N0 
L PBMC, LNL 
TIL cell count too low 
 
CD4CD25 typing 
 
15 93 F Adenocarcinoma
T3N0 
R PBMC, TIL, LNL Analysing CD4 
phenotype  & 
Functional analysis of 
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whole TIL population 
 
16 70 M Adenocarcinoma
T4N0 
L TIL, LNL 
No blood obtained 
Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
17 60 M NHL R PBMC, TIL, LNL Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
but unexpected 
histology therefore 
excluded 
 
18 73 M Adenocarcinoma 
with 
adenocarcinoid 
R PBL, LNL, TIL 
There were no viable 
LNL seen on flow 
cytometry 
 
Analysing CD4 
phenotype  & 
Functional analysis of 
whole TIL population 
 
19 82 F Adenocarcinoma
T3N1 
L PBMC, LNL,  
TIL not harvested as 
validating MACS without 
TIL first 
Analysing CD4 
phenotype and 
separation into 
functional subgroups 
(MACS) 
 
20 65 M Adenocarcinoma
T3N0 
L PBMC, TIL only as aim 
was to validate MACS 
with TIL 
 
Analysing CD4 
phenotype and 
separation into 
functional subgroups 
(MACS) 
SEPARATION 
21 81 F Adenocarcinoma
T3N0 
R PBMC, TIL only as aim 
was to validate MACS 
with TIL 
 
Analysing CD4 
phenotype and 
separation into 
functional subgroups 
(MACS) 
 
22  EC Adenocarcinoma
T3N0 
R PBMC Tumour was too 
small radiotherapy 
 
 
 
Analysing CD4 
phenotype and 
separation into 
functional subgroups 
(MACS) 
 
23 55 M Adenocarcinoma
T4N0 
L PBMC, LNL, TIL Analysing CD4 
phenotype and 
separation into 
functional subgroups 
(MACS) 
 
24 55 F Adenocarcinoma
T2N0 
L PBL, LNL, TIL 
LNL became infected in 
culture  
TIL: no cells 
 
Analysing CD4 
phenotype and 
separation into 
functional subgroups 
(MACS) 
90 
 
 
25  F Adenocarcinoma
T2N1 
 
L PBMC, TIL, LNL, MIL HOMING phenotype 
analysis 
26 68 M Adenocarcinoma
T3N0 
 
R PBMC, TIL, LNL, MIL HOMING phenotype 
analysis 
27 66 M Adenocarcinoma
T3N2 
 
R PBMC, TIL, LNL, MIL HOMING phenotype 
analysis 
28 97 F Adenocarcinoma
T3N0 
 
R PBMC, TIL, LNL, MIL HOMING phenotype 
analysis 
29 76 M Adenocarcinoma
T4N1 
 
R PBMC, TIL, LNL, MIL HOMING phenotype 
analysis 
30 72 M Adenocarcinoma
T3N0 
 
L PBMC, TIL, LNL, MIL HOMING phenotype 
analysis 
31 75 F Adenocarcinoma
T1N0 
 
R PBMC, TIL, MIL 
Not enough TIL obtained 
to analyse flow cytometry 
data 
HOMING phenotype 
analysis 
32 57 M Adenocarcinoma
T3N1 
 
R PBMC, TIL, MIL 
Not enough TIL obtained 
HOMING phenotype 
analysis 
33 70 M Adenocarcinoma
T3N0 
 
L PBMC, TIL, MIL 
Not enough TIL obtained 
to analyse flow cytometry 
data 
HOMING phenotype 
analysis 
34 70 M Adenocarcinoma
T3N2 
 
L PBMC, TIL, MIL 
 
HOMING phenotype 
analysis 
35 72 M Adenocarcinoma
T3N0 
 
L PBMC, TIL, MIL HOMING phenotype 
analysis  
36 69 M Adenocarcinoma 
T4N0 
 
L PBMC, TIL, MIL 
 
HOMING phenotype 
analysis 
37 82 F Adenocarcinoma 
T3N1 
L PBMC, LNL IL-4 RECEPTOR 
BLOCKING 
EXPERIMENT 
 
38  M Adenocarcinoma 
T3N2 
L PBMC only required ELISA VERSUS 
ELISPOT 
EXPERIMENT 
 
39 75 M Adenocarcinoma 
T3N0 
 
L TIL only required Separation into 
functional subgroups 
based on cell surface 
markers (FACS) 
40 46 F Adenocarcinoma 
T3N0 
 
L TIL Separation into 
functional subgroups 
based on cell surface 
markers (FACS) 
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Table 3.1 Patient characteristics and experimental use of specimens 
 
Median age was 71.4 years, (range 46-97 years).  M: F ratio was 1:0.6. 32% of patients 
had right sided tumours.  At the time this work was undertaken, both the degree of 
lymphocytic infiltration and mismatch repair gene status were not routinely undertaken for 
diagnostic or prognostic purposes and the results were not available. 
 
 
 
3.3 Tissue Harvesting 
 
Several factors had a bearing on successful harvesting of adequate numbers of TIL, and 
these included, firstly, the ability to take a sizeable biopsy, secondly, repeated cycles of 
disaggregation to optimise the number of cells extracted, and thirdly, attempting to purify 
the suspension without simultaneously losing large numbers of TIL.  As a protocol was 
agreed with the pathologist for the handling of the specimen, which limited the size of the 
biopsy to up to one fifth of the tumour, the weight of biopsies was variable and ranged 
from 0.4g – 3g.  
 
 
 
 
 
 
41 68 M Adenocarcinoma 
T1N0 
 
L TIL Separation into 
functional subgroups 
based on cell surface 
markers (FACS) 
42 80 M Adenocarcinoma 
T3N2 
 
L TIL Separation into 
functional subgroups 
based on cell surface 
markers (FACS) 
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3.4 Identifying TIL with Flow Cytometry 
 
Flow cytometry is used to calculate the number of lymphocytes stained with an antibody 
labelled with fluorochrome as a percentage of the total lymphocyte population (identified 
by CD3 MAb linked to an alternative fluorochrome).  Cells were prepared for flow 
cytometry as per section 2.2.2.  For the analysis, a forward versus side scatter plot is 
obtained which plots cells based on their size and granularity.  Cells of a specific size and 
granularity will disperse light in a similar manner and hence appear as a distinct 
population; hence it is possible to capture the lymphocyte population from amongst other 
haematopoietic cell types (Fig. 3.1).  The gated area may not contain absolute numbers of 
CD3 cells, but as expression of the marker of interest is expressed as a percentage, this is 
not essential. As gates are increased in size there is an increased likelihood that other cell 
types may be included in the analysis, including dead or dying cells that tend to non-
specifically take up stain. 
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The flow cytometry plot obtained when analysing TIL is difficult to interpret, as there is 
often not an easily recognisable lymphocyte population, due to increased contamination 
with other cell types.   
 
Antibodies to cell surface markers of interest (e.g. CD3 and CD4), are attached to various 
fluorochromes that will emit light of variable wavelengths.  The flow cytometer can 
measure light of several set wavelengths in pre-determined channels, but prior to each use 
the flow cytometry machine must be compensated so that the spectral overlap of the 
various fluorochromes used is minimised. When an analysis is undertaken, it becomes 
apparent if there is a large population of dying cells that are taking up stain as clear 
populations are not seen, but instead a gradual smear that tends to occur in a diagonal 
direction moving away from the unstained cell population (as seen in Fig. 3.2). Dying cells 
can also be identified as they usually take up isotype control. An alternative is using the 
stain propidium iodide, a fluorescent stain for DNA, but its use does have drawbacks as it 
can make compensation of the flow cytometry machine more difficult to achieve.  It was 
not used for this reason. 
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Several different methods to accurately gate on the TIL CD3 population were attempted; 
for example, (1) by predicting the population just by looking at the scatter plot for TIL 
(this is what is routinely done for PBL or LNL) (2) first identifying all CD3+ cells on a 
histogram and gating on this population to see where they lie on a scatter plot, (3) setting 
the gate using PBMC and transferring the same gate to a scatter plot from TIL. The best 
method to identify the TIL population of interest proved to be setting the gate using 
PBMC and transferring the same gate to a scatter plot from TIL, and subsequent analysis 
of CD4 versus CD3 expression produced clean data (Fig. 3.3).  When I first identified all 
the CD3+ cells on a histogram to see where they lay on a scatter plot, there was no clear 
population identified but instead a large amount of uptake spread over a wide area, 
probably because various cell types damaged by the process of mechanical disaggregation 
were present in the TIL suspension. 
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The implications are that setting the gates in this way we are (1) assuming that TIL have 
the same size and granularity properties as PBL and (2) may be excluding some viable 
lymphocytes, however, there was no alternative found that could ensure all CD3 cells were 
captured and at the same time produce clean staining of the TIL population to allow 
accurate percentages of cell surface marker expression to be calculated.  The drawback is 
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that if, for example, a certain homing marker happened to be expressed on TIL that were 
slightly different in size or granularity than the total population of TIL, then the results 
could be affected.  To ensure this method of identifying the TIL population was robust, the 
various different methods of setting the gate (as above) to capture CD3+ cells was 
repeated with every analysis performed.  In conclusion, methods of obtaining a suspension 
of TIL using mechanical disaggregation were developed.  Analysing the cytometry results 
is dependent on the correct localisation of the TIL population, but hampered by the 
presence of other cell types or dying cells.  
 
Refining the methods of tissue harvesting and subsequent analysis with flow cytometry 
was an important process if these methods are to be used to analyse potential cell surface 
and functional biomarkers of CD4+ TIL as part of future trials.  
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4 Cell Surface Phenotype of Tumour Derived CD4 Cells from 
Colorectal Cancer 
 
4.1.1 CD4 T-cells in colorectal cancer  
 
 
We know that the most abundant immune cells in CRC are CD4+ T-cells (section 
1.1.2.1), and a more pronounced lymphocytic response correlates to a better 
prognosis.   There is variation in the ratio of CD4: CD8 T-cells in CRC and this also 
appears to have prognostic implications.  We do not know if the ratio of CD4+ T-cells 
in tumour is merely a reflection of the percentage of lymphocytes in peripheral blood 
that are CD4+, or if there is selective uptake of this subgroup. 
 
Aim:  Compare the proportion of CD4 T-cells within the lymphocyte population in 
TIL, LNL and PBL to ensure results are comparable with published literature, and to 
assess whether the percentage of CD+ T-cells in TIL is a reflection of the percentage 
of CD4+ T-cells in matched PBL. Validate the use of flow cytometry for 
characterising phenotypic profiles in TIL.   
Samples: PBL n= 15, LNL n= 12, TIL n=12 
There was an attempt to obtain paired samples from patients 1 – 17 in table 3.1. 
Paired samples of PBL, TIL and LNL were used from 12 patients.  Unpaired data was 
available from PBL from patient numbered 23 using surplus cells. The data from 
patient 17 was excluded as the histology revealed lymphoma.  In PBL from patient 
number 15 there was inadequate staining of CD3, and in patient number 16 there was 
no blood obtained.  In patients numbered 7 and 9 the tumour was too small, and in 
patient number 13 there was not enough viable TIL obtained. 
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Healthy donors n=9 
Fresh, unfixed samples were used in all cases. 
Assay: Flow cytometry (section 2.2.2) using saturating concentrations of anti CD4 
PE-conjugated (Coulter, UK) and CD3 FITC-conjugated mouse anti-human IgG1 
clone UCHT1 (BD Pharmingen).  In all cases a negative control was used with no 
antibody added in addition to corresponding IgG1 and IgG2a isotype controls being 
used.  The assays for samples from patients were performed at different time points, 
but for the first nine patients tested synchronous assays were performed with a sample 
from one lab donor as positive controls.  Acquisition and analysis of data was all 
performed on the same Coulter Epics XL-MCL flow cytometer (Beckman Coulter). 
Compensation of the machine was performed prior to starting each assay (with 
intensely stained FITC and PE conjugated antibodies) to avoid spectral overlap 
between the fluorochromes used.   
Analysis: Analysis of 2-colour flow cytometry data was performed using WinMDI 
2.8 (Joseph Trotter). Linear regression was performed to assess correlation of CD4 
expression between matched PBL and TIL samples. 
 
Using 2-colour flow cytometry CD3 and CD4 staining of peripheral blood, tumour and 
lymph node lymphocytes were compared.  An example of the staining achieved using TIL 
is seen in Fig. 4.1, and the cumulative results of all samples analysed is seen in Fig. 4.2. 
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This initial experiment demonstrated that the median proportion of CD4+/CD3+ TIL was 
65%.  This is similar to what has been previously described by Diederichsen et al who 
found the median ratio of CD4: CD8 to be 2.2 (7).  In PBL, the median expression of CD4 
was 58%.    PBL were also obtained from nine volunteers from the institute of cancer 
studies.  In peripheral blood from the control group, the median expression of CD4 was 
53%.  Mesenteric lymph node was obtained from twelve patients and has shown median 
expression of CD4+ to be 74%.  This is high compared to published literature of CD4+ 
counts in lymph nodes from other tumours.  Fatturossi et al have shown that LNL from 
patients with cervical cancer had a CD4+ count of 49% +/- 7, and with endometrial cancer 
a CD4+ count of 48% +/- 12 (171).  However, a study assessing the CD4/CD8 ratio in 
lymph node fine needle aspirates from 837 patients (to determine whether this ratio could  
be used to aid diagnosis of Non-Hodgkins Lymphoma) found that the mean ratio in 
normal ‘reactive’ nodes was 7.5 (range 4.1-29) (172). 
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The steps taken to ensure robustness of all the flow cytometry data include preparation of 
all cell suspensions in a standardised manner, with only fresh cells being used (i.e. there 
was no fixation of cells that would have allowed analysis to be performed at a later date). 
Negative controls and isotype controls were used, and the same clones of antibodies were 
used for all experiments.  Compensation of the cytometer was performed prior to every 
analysis to avoid spectral overlap and measurement artefacts.  A large number of events, at 
least 10,000 cells were analysed for every antibody tested, as this was the routine method 
of showing validity of the assay at that time. It was not routine to undertake the whole 
staining procedure in duplicate or triplicate, although, more recently some published flow 
cytometry data has been presented in duplicate or triplicate.  This initial study has shown 
that I could obtain material to work with and established the technique of doing so. 
 
Using a regression line, to explain how much the CD4+ count in PBL explains the 
variability in TIL CD4+ count, the relationship between CD4 expression on PBL versus 
TIL was weakly positive as R2= 0.3, suggesting 30% of the variability of TIL was 
dependant on PBL expression, and that the other 70% of variability of the CD25High TIL 
was due to some other factor(s).  Therefore, it is possible that uptake of TIL into tumour is 
somehow selective. The p value tells you how confident you can be that each individual 
PBL value has some correlation with the dependant TIL value (p=0.0784). 
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The next experiments were to dissect the CD4+ population into subgroups according to the 
expression of cell surface protein markers which might be of relevance as markers of 
functional subgroups. 
 
4.1.2 Expression of CD25 in colorectal cancer 
 
We know that various sub-types of CD4+ T-cells exist.  Type -1 THC can contribute to 
anti-tumour responses, whereas TREG can dampen down the immune response 
(sections1.4.5 and 1.4.6).  At the start of this study the presence of TREG in CRC was not 
known.  To test the hypothesis that the CD4+ population in colorectal cancer is 
heterogeneous including various different functional sub-types such as those with 
regulatory functions I first examined expression of CD25 using flow cytometry, and when 
antibodies for FoxP3 became available, I retrospectively examined FoxP3 expression 
using immunohistochemistry in paired samples. 
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Aim: Using flow cytometry, compare the proportion of CD4+ lymphocytes 
expressing CD25+ within TIL versus PBL and LNL  
Patients: PBL n=22, LNL n=13, TIL n=13  
There was an attempt to obtain paired samples from patients numbered 1 -24 in table 
3.1.  Data from patient number 17 was excluded as histology revealed lymphoma.  
Blood was not obtained from patient number 16.  In 4 patients tumour was too small 
to harvest (patients numbered 2, 7,9,22 in table 3.1).  In seven patients not enough 
viable or stained TIL were obtained for flow cytometry (patients numbered 
1,8,10,12,13,14, 24). In one patient I did not harvest TIL as they were not required for 
the validation functional study that was being performed (patient 19). 
There were 11 paired PBL, LNL and TIL samples 
Healthy donors n=13 
Fresh, unfixed samples were used in all cases. 
Assay: Flow cytometry using anti CD4-FITC (BD Pharmingen), and CD25 PE-
conjugated mouse anti-human IgG2a clone B1.49.9 (Beckman Coulter).   (Negative 
controls and corresponding IgG1 and IgG2a isotype controls were also used). (See 
flow cytometry methods section 2.2.2). 
The assays for samples from patients were performed at different time points, but 
synchronous assays were performed with a sample from one lab donor. Acquisition 
and analysis of data was all performed on the same Coulter Epics XL-MCL flow 
cytometer (Beckman Coulter). Compensation of the machine was performed prior to 
starting each assay (with intensely stained FITC and PE conjugated antibodies) to 
avoid spectral overlap between the fluorochromes used.  At least 10,000 events were 
measured in each case, but each specimen was only tested once for each antibody( or 
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isotype). 
Analysis: Analysis of flow cytometry data was performed using WinMDI 2.8 (Joseph 
Trotter). Mann-Whitney and linear regression analysis comparing the CD4+CD25+ 
expression in PBL versus TIL in patients with CRC.   
 
Flow cytometric staining of lymphocytes with CD25 is a continuous rather than distinct 
subgroup.  An example of the type of staining we achieved with TIL is seen in Figure 4.4, 
and this is consistent with published findings.  
 
The median level of expression of CD25 as a percentage of CD4 was 3.2%, 4.6% and 
10.7% in PBL, LNL and TIL respectively (Figure 4.5).  We assumed this data was not of 
normal distribution, and therefore used a Mann Whitney test to determine whether there 
was a significant difference in the expression of PBL versus TIL.  The p value was just 
outside the level of significance at 0.054.  Control PBL were obtained from 13 laboratory 
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donors, and were not matched for age or sex, as the main reason for recruiting a control 
group was to act as a positive control (and also to validate the functional experiments that 
are explained in the following chapter) rather than identify a true difference in the 
percentage of peripheral TREG between patients with or without CRC.  In the control group, 
median expression was 3.4% (range 0.8 – 11.7), which was similar to the values seen for 
patients with colorectal cancer. 
 
 
As previously discussed, it has been shown that the regulatory subgroup of cells is likely 
to lie in the CD25HIGH region, defined as those cells shifted further to the right than the 
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CD4-CD25+ subgroup (Figure 4.6).  Each specimen was analysed to determine the CD25 
HIGH percentage (n=12 as one data file corrupted).  
 
Figure 4.7 shows the distribution of CD4CD25HIGH cells, and it can be seen that there 
was a higher percentage of these putative regulatory T-cells in tumour than in peripheral 
blood lymphocyte populations.  The median expression of CD25HIGH cells in the CD4+  
population was 1.8% in PBL (range 0-9.7%), 0.8% in the control group (range 0-3.8%), 
3.1% in LNL (range 0-14.7%) and 7.9% in TIL (range 0-21.9).  Using Mann Whitney 
there is a high probability that there is a real difference in the expression of CD25High in 
PBL versus TIL, p=0.0013. 
107 
 
 
 
 
 
When using flow cytometry to analyse the expression of a cell surface marker that is 
present on only a small percentage of cells there is the risk that errors in calibration or 
compensation could result in erroneous results.  Dead or dying cells could also cause an 
apparent difference.  However, the steps taken to set the compensation correctly on the 
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cytometer, and the use of isotype control antibodies aim to avoid this.  As previously 
mentioned, a weakness of this study was that a marker to exclude dying cells such as 
propidium iodide was not used. It had been considered at the time of the study but 
previous experience in the laboratory (with other studies) had found that adequate 
compensation was difficult to achieve when it had been used.  
 
In order to analyse whether the expression of CD25HIGH on TIL was a reflection of 
expression in PBL or due to other factors (e.g. selective uptake or differentiation into TREG 
once in peripheral tissues), a regression line analysis was performed (Fig 4.8). It is highly 
unlikely that CD25High expression on TIL is dependent on the amount of expression in 
PBL. 
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4.1.3 Expression of Foxp3 in colorectal cancer 
 
 
CD25 can also be a marker of T-cell activation (although these cells usually show 
CD25LOW expression), therefore CD25 is not completely reliable for identifying a 
regulatory subset of cells, so it was necessary to confirm the presence of TREG by assessing 
expression of FoxP3, a nuclear transcription factor inhibiting transcription of IL-2, and 
thought to be the most specific marker of TREG function (described in section 1.4.6). 
 
Aim: Using immunohistochemistry to determine the presence of FOXP3 positive 
lymphocytes in CRC 
Specimens: Paraffin sections of colorectal cancer from 14 patients (Table 3.1). These 
were paired samples with CD4CD25HIGH flow cytometry.  
Method: Agitated Low Temperature Antigen Retrieval and Immunohistochemistry.  
(sections 2.2.12 and 2.2.13). Sections were deparaffinised with Xylene, and hydrogen 
peroxide used to block endogenous peroxidises. Buffering at low temperature 
overnight allowed epitope retrieval. Slides were blocked with sheep serum to prevent 
non specific binding of the primary antibody. A saturating volume of anti-human 
FoxP3 goat polyclonal primary antibody was used. Control slides with no stain and 
with IgG isotype were used. Counterstaining with haematoxylin to provide contrast 
was performed. 
Analysis: Consultant Pathologist opinion and photography. 
 
Antibody to foxp3 for immunohistochemistry only became available during the period of 
study, and antibody for flow cytometric staining was not yet available.    Paraffin sections 
of colorectal cancer from 14 patients were obtained from the pathology department at 
University Hospital Birmingham.  Samples from all patients had also been used for flow 
cytometry for CD4CD25 analysis.  Dr Phillipe Tanniere, a Consultant Pathologist at 
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University Hospitals Birmingham NHS Trust assessed each, and confirmed that Foxp3 
positive cells could be identified in all 14 patients.  In retrospect, this finding may have 
been more robust if other tissues were used to provide positive and negative controls, and 
if the analysis was repeated by a second pathologist.  An example can be seen in figure 
4.9, where it is observed that Foxp3 positive cells were seen in a scattered intra-epithelial 
distribution. 
 
 
The conclusion from these initial flow cytometry experiments dissecting CD4+ TIL is the 
demonstration of putative TREG in CRC. The presence of FOXP3+ intraepithelial 
lymphocytes on immunohistochemistry confirms that TREG are present.  Although in these 
experiments the sample sizes are small, there is a suggestion that the expression of 
CD4+CD25HIGH is higher in tumour than peripheral blood lymphocytes.  The next aim 
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was to investigate the presence of other subsets of CD4+ TIL by analysing homing marker 
expression. 
4.1.4 Homing marker expression 
 
 
We wished to further characterise the phenotypic profile of TIL, and in particular assess 
markers that could signify cells of a specific functional response.  We know that certain T-
cell homing marker receptors have been associated with inflammatory tissues (section 
1.4.7.5).  Homing marker expression in TIL from CRC was not known at the start of this 
study (section 1.4.7.7), so I wished to determine heterogeneity of homing marker 
expression by TIL and ascertain whether there could be selective uptake of TIL expressing 
any of these receptors.  
  
Aim: to assess the expression of a panel of 18 homing markers on TIL, PBL, LNL 
and MIL 
Patients: Paired samples were used. PBL n=6, TIL n=6, MIL n=6, LNL n=5.  In one 
patient although LNL had been present on light microscopy prior to staining, they had 
been lost due to an unknown technical issue when it came to flow cytometric analysis. 
Fresh unfixed samples were used. 
Assay: 3-colour flow cytometry for CD3, CD4 and CCR1 (clone 53504.111), CCR2 
(48607.121), CCR3 (61828.111), CCR6 (53103.111), CXCR4 (44716.111), CXCR5 
(51505.111), CXCR6 (56811.111) (R&D systems UK); CCR4 (1G1), CCR5 (2D7), 
CCR7 (3D12), CXCR3 (1C6) (Pharmingen, UK), LFA-1 (HI111), PSGL-1 (KPL-1), 
CLA (HECA-452) (Pharmingen) and VLA-4 (P4G9) (Abcam).  (section 2.2.2) 
The uptake of various isotype controls were analysed, including IgG1, IgG2A, 
IgG2B, Rat IgG, and IgM, to cover each class of homing marker tested.  The assays 
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for samples from patients were performed at different time points. Acquisition and 
analysis of data was all performed on the same Coulter Epics XL-MCL flow 
cytometer (Beckman Coulter). Compensation of the machine was performed prior to 
starting each assay (with intensely stained FITC, PC-5 and PE conjugated antibodies) 
to avoid spectral overlap between the fluorochromes used.  At least 10,000 events 
were measured in each case, but each specimen was only tested once for each 
antibody (or isotype). 
Analysis: Analysis of flow cytometry data was performed using WinMDI 2.8 (Joseph 
Trotter). Graphical analysis and significance testing was performed using GraphPad 
PRISM version 4.0. 
 
Three-colour flow cytometry was used and one example of the type of staining when this 
technique is used to assess homing marker expression in TIL can be seen in Figure 4.10.  
In some homing markers, this expression was seen as a distinct sub-group, and in others 
the pattern of staining was as a low-grade continuation of the spectrum (like CXCR3). 
Invariably, isotype uptake was higher for TIL and MIL than it was for PBL or LNL.  As 
the corresponding level of background staining seen in the isotype control was subtracted 
from the amount of staining seen for each homing marker in each tissue type, it would 
mean that when assessing homing markers with naturally very high levels of staining, the 
calculated level could be artificially lower than its true value.  Figure 4.11 shows an 
overview of the results for expression on CD4+ cells, of all markers tested in paired PBL, 
LNL, TIL and MIL from the first six patients in whom the whole panel of 18 homing 
markers were tested. Each marker will then be discussed in detail. 
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4.1.4.1 Adhesion molecules associated with inflammation 
 
PSGL-1 is an adhesion molecule associated with binding to E- and P-selectin at sites of 
inflammation.  Studies have shown that PSGL-1 is important for the binding of TH1 cells 
and not TH2 cells and mediates migration into inflamed skin (173). A recent study 
assessing the difference in expression of PSGL-1 on CD4+ cells in patients with multiple 
sclerosis versus healthy individuals found a difference of 78% versus 48% (174). Figure 
4.12 shows an example of PSGL1 expression from the samples from one patient.  
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The isotype staining for PBL was low in all cases. In other tissue types, the isotype 
staining, as seen in the figure could be higher. The marker (M1) is set using the cells that 
do not contain primary antibody so that the level of isotype uptake can be determined. It is 
a limitation of flow cytometry that both the gate (R1) that is set on the scatter plot to 
identify the lymphocyte population, and the marker (M1) that measures the number of 
cells that exhibit fluorescence intensity above the level set by the observer.  This is 
discussed further in chapter 6.  Once set, the position of M1 was kept constant for each 
tissue type for the whole panel of homing markers. When analysing the results, the 
percentage expression of the isotype was subtracted from the percentage expression of the 
marker in question.  
 
The cumulative results from six patients (Fig 4.14) show that we found that levels of 
expression of PSGL1 were highest in PBL, but interestingly they appeared to be higher in 
TIL than in MIL. This may indicate some selective uptake to tumour sites. There is a 
paucity of published results stating levels of expression of this adhesion molecule in the 
literature for comparison.    
 
VLA-4 is an adhesion molecule that binds to VCAM-1 after activation at a site of injury.  
A study in mice from 2009 has shown that VLA-4 was preferentially expressed on TH1 
cells, and was required for these cells to be taken up into tumours (175).   An example of 
the staining seen in one patient can be seen in Fig. 4.13. Overall, we found the levels of 
expression to be similar in both PBL and TIL (78 versus 74% respectively) (Figure 4.14).  
But again, the level of expression was higher in TIL than in MIL (74% versus 47%). 
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4.1.4.2 Homing markers associated with gut homing 
 
As previously described 47 binds to MAdCAM to enable T-cells to enter gut epithelium 
(section 1.4.7.6).  Expression of 47 in CD4+TIL was 39.1% (interquartile range 16.4 – 
58.1%) versus 27.15% in PBL (range 14.55 – 40.55%), so there was no significant 
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difference between these groups (Fig. 4.15).  A study by Meenan et al in 1997 had shown 
55% expression in PBL and 49% in MIL in patients with mucosal inflammation (176).  
 
 
 
Overall there was no increase in CCR9 expression in CD4+ TIL versus CD4+PBL (1.95 
versus 1.15%).  TIL from one patient had shown CCR9 expression of 60%, but the others 
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all ranged from 0 - 4.9% expression.  This patient had a left sided Dukes stage C tumour.  
The other 4 patients tested had Right sided Dukes B or C tumours. 
 
4.1.4.3 Markers associated with skin epithelial migration 
 
CLA is a modified version of PSGL-1 which is specific for skin homing (177).  CCR4 has 
also been shown to be involved in skin homing (178), but it is described later as it is also 
associated with a TH2 response.  Expression of CLA receptor was very low in PBL and 
absent in the other cell types (Fig. 4.16).  CCR10 ligand has been shown to be involved in 
skin homing in mouse studies (179), but antibodies to CCR10 were not available to us at 
the time of research.  
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4.1.4.4 Homing markers associated with lymph node homing 
 
Lymph node binding is initiated by the binding of CD62L, then activation of CCR7, 
followed by LFA (section 1.4.7.3).  CD62Ligand, or L-selectin, as expected, had higher 
levels of expression in PBL and LNL than TIL and MIL due to a higher proportion of 
memory rather than naïve cells (Fig. 4.17).  In PBL, 54% of CD4+ T-cells were CCR7+ 
(interquartile range 26.15 – 68.55%).  In LNL, CCR7 expression was lower than I 
expected, the reasons for this are unclear.  In the periphery, differentiated T-cells are 
known to lose CCR7 expression.  In TIL, average expression was 13.4% (range 5.05 – 
30.05%), concluding that either T-cells that are CCR7+ are less likely to enter peripheral 
tissues or they lose CCR7 expression once they become intraepithelial lymphocytes.   
 
LFA which is known to be involved in homing to peripheral tissues as well as lymph 
nodes was present on most PBL and LNL, and there were high levels of expression on TIL 
and MIL.  CXCR5 is responsible for homing of THC that migrate to the B-cell follicle of 
the lymph node, and it has also been shown to be present on peripheral CD4 cells that 
have down regulated their CCR7 expression.  When assessing expression of CXCR5, 3 
patients had much higher levels of expression in TIL compared to their corresponding 
PBL.  In TIL, median expression of CXCR5 was 19.70 % (interquartile range 5.95-
43.55%).  In PBL median expression is 11.80% (5.45-19.55%).   
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4.1.4.5 Homing markers associated with a TH2 response 
 
Of the homing markers associated with a T-Helper-2 response, CCR3 had shown very low 
levels of expression in all groups (Fig. 4.18).  CCR4 expression was 18.45% for CD4+ 
PBL (interquartile range 12.45 – 26.35%) and 5.3% in CD4+TIL (interquartile range 1.05 
– 29.65%).  CCR8 was not tested, as an antibody to this receptor was not available the 
time of the study.  
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4.1.4.6 Homing markers associated with a TH1 response 
 
We know that several homing markers (CXCR3, CCR5, CCR6 and CXCR6) have been 
shown to be present in inflammatory tissue where the predominant cytokine response 
involves IFN-γ release (section 1.4.7.5).  Analysis of the first 6 patients samples used in 
the series assessing homing marker expression revealed that markers CXCR6, CCR5 and 
CCR6, appeared to be expressed more frequently in TIL than PBL. At this stage the 
possibility that these findings could be merely due to a difference in the percentage of 
naive: memory cell ratio that exists between PBL and TIL, rather than selective uptake, 
was raised. The expression of these markers plus CXCR3 (not excluded based on the 
results of this small series of results) were then tested in a further six patients and we 
progressed to 4-colour flow cytometry so that we could also assess the percentage of naive 
T-cells.   
 
Unfortunately, of these further six patients, data was collected from only three; in one 
patient levels of TIL obtained were too low even prior to staining, and in two patients an 
adequate TIL population could not be identified at the time of flow cytometry. The data 
for these markers for all nine patients are presented together. 
 
Aim: to assess the expression of a panel of 4 homing markers on TIL, PBL, LNL and 
MIL and to determine if there was a true difference in expression between tissue 
types, or if this was as a consequence of variation in Naive: Memory cell ratio. 
Patients: Paired samples were used. PBL n=9, TIL n=9, MIL n=9, LNL n=9. (For 
data on naive: memory cell ratios n=3 for each).  Dropout rate n=3. Fresh unfixed 
samples were used. 
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Method: 4-colour flow cytometry for CD3, CD4, CD45RA and a panel of 4 homing 
markers (section 2.2.2). CXCR6 (56811.111) (R&D systems UK); CCR5 (2D7), 
CCR6 (53103.111) and CXCR3 (1C6) (Pharmingen, UK). 
The uptake of various isotype controls were analysed, including IgG1, IgG2A, 
IgG2B, Rat IgG, and IgM, to cover each class of homing marker tested.  The assays 
for samples from patients were performed at different time points. Acquisition and 
analysis of data was all performed on the same Coulter Epics XL-MCL flow 
cytometer (Beckman Coulter). Compensation of the machine was performed prior to 
starting each assay (with intensely stained FITC, PC-5 and PE conjugated antibodies) 
to avoid spectral overlap between the fluorochromes used.  At least 10,000 events 
were measured in each case, but each specimen was only tested once for each 
antibody (or isotype). 
Analysis: Analysis of flow cytometry data was performed using WinMDI 2.8 (Joseph 
Trotter). Mann-Whitney test to assess significance of differences of expression of 
certain markers between PBL and TIL. Correlation co-efficient between markers of 
interest to generate a hypothesis that there may be ‘signatures’ of homing markers 
expressed by TIL. 
 
The pattern of expression of CXCR6 on CD4+PBL was low, and on the histograms it took 
the form of a continuation to the right from the negative population rather than a discrete 
population (Fig. 4.19). Again, isotype staining was higher in tissues other than PBL. Once 
set, the position of the marker, M1 was kept constant for each tissue type, and when 
analysing the results, the percentage expression of the isotype was subtracted from the 
percentage expression of CXCR6.  
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Figure 4.20 shows median expression of CXCR6 in PBL was 6.3% (interquartile range 
1.25-10.10%).  In contrast, the pattern of expression in TIL revealed a discrete population 
of CXCR6+ cells. In TIL, the percentage expression of CXCR6 was significantly higher, 
where median expression was 30.30% (interquartile range 22.65-39.80%).  In each of the 
nine patients tested, CXCR6 expression in TIL was higher than the corresponding level in 
PBL.  The difference in expression between PBL and TIL was statistically significant 
(p<0.0001) using the Mann Whitney test.  As a large number of comparisons has been 
made (18 homing markers and four tissue types equates to 54 comparisons), a bonferroni 
correction would mean that a result would be statistically significant if p>0.0009 (when 
using p<0.05 as the normal level of significance). 
 
 
 
Reports of CXCR3 expression by colorectal TIL have shown conflicting results (sections 
1.4.7.6 and 1.4.7.7).  We found no difference in the median expression of CXCR3 by PBL, 
TIL and MIL (5.8, 8.5 and 7.6% respectively) (Fig. 4.21).    
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At least two studies have shown expression of CCR5 on colorectal TIL (141) (143).  We 
also found levels of expression of CCR5 to be higher in TIL than PBL, with median 
expression 26.7% and 1.9% respectively. Median expression in MIL was 19.2%.   When 
comparing the results of all four types of lymphocytes, the differences seen were not 
statistically significant, but this is perhaps due to the small sample size and the fact that 
there are also high levels of expression in normal mucosa. 
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CCR6 has been shown using immunohistochemistry, to be present on the epithelium of the 
colon, colonic tumours and liver metastasis (180).  It is also been shown that in PBL, 
CCR6 is expressed on memory T-cells, and that almost all α4β7 cells (that are involved in 
gut homing) were CCR6 positive (181).  We found a higher median expression of CCR6 
on TIL, compared to PBL, LNL and MIL (32%, 17.7%, 10.6% and 12.6% respectively).  
These differences were not statistically significant using a Mann Whitney Test (p=0.1797). 
Figure 4.22 allows comparison of homing marker expression between paired samples of 
PBL, TIL and LNL.  For CXCR6 and CCR5 expression, the level of staining was higher in 
TIL than both PBL and LNL for every paired sample.   
 
 
In order to ensure that the differences in the level of expression of homing markers was 
not merely due to variation in the number of naive versus memory cells, 4 colour flow 
cytometry was performed using CD45RA.  As expected, the numbers of naive CD45RA+ 
cells were much lower in TIL and MIL than PBL (median percentages 9.3, 10.5 and 
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32.5% respectively). The variability in naive: memory cell ratio between populations of 
lymphocyte was not the reason for differences in homing marker expression (fig 4.23). 
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In order to determine whether it might be possible to describe a ‘signature’ of homing 
markers associated with inflammation in TIL from colorectal cancer we looked for trends 
in patients with the highest levels of  CXCR6 expression to see if they also had significant 
expression of CCR5 and CCR6 (Figure 4.24).  We found that there was correlation 
between CXCR6 and CCR5 expression (Pearson correlation coefficient, R = 0.6) and 
CXCR6 versus CCR6 (R =0.71).   
 
We concluded from these results that we could identify sub-populations within colorectal 
TIL.  We have identified a population of cells that can be defined by their homing marker 
expression, particularly CXCR6 expression, and a further subpopulation of putative TREG 
as defined by CD25HIGH expression.  The next step would be to develop the methods that 
might allow us to analyse the functional ability the subpopulations we have defined.  
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5 Selection of Functional Subtypes 
The aim with the groups of experiments described in this chapter was to investigate 
whether we were able to extract TIL from fresh tumour samples, stimulate the total 
lymphocyte population and elicit a response that could be measured in a standardised 
manner.  Functional studies of lymphocytes are well documented in experiments involving 
peripheral blood lymphocytes, but the objective was to determine if the same methods can 
be transferred to colorectal TIL.  Initially, cytokine ELISA was used to assess production 
of four cytokines of interest; IFN-, as a marker of a T-Helper 1 anti-tumour response, 
TGF- and IL-10 as markers of a regulatory immunosuppressive response, and IL-4, for a 
T-Helper 2 response.   
 
Phenotypic subgroups identified in the previous chapter, were used to identify whether we 
could elicit a different response when separating TIL; specifically CD4+CD25+ versus 
CD4+CD25-, and CD4+CXCR6+ versus CD4+CXCR6- subsets.  For this, two different 
methods of separation were employed; Magnetic Cell Sorting (MACS), and Flow Assisted 
Cell Sorting (FACS). 
 
An overview of the study design can be seen in figure 5.1. Steps would include validating 
the methods of extracting TIL, ensuring adequate numbers of TIL, and accurately 
predicting how many TIL are actually used for each assay.  Assessment of the various 
methods of lymphocyte stimulation available to determine the method that produces an 
optimal response and validation of the length of time cells should be cultured to allow 
maximal cytokine release before the supernatant is removed for analysis was undertaken. 
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5.1.1 Assessment of methods of cell stimulation 
 
Several methods to stimulate T-cells based on activating the T-Cell Receptor exist (see 
section 1.3.3.2), but the optimal methods for eliciting a response, particularly with the use 
of TIL was not known. 
Aims: (1) Determine optimal method of stimulating PBL, TIL and LNL. 
(2) Determine number of cells required per cell culture well to elicit a response 
(3) Determine the optimal length of time of cell stimulation 
Patients : 
PBL from healthy lab donors: 2  
 PBL and TIL from patients: n=1 
Assay: ELISA IFN-gamma (section 2.2.5) 96 well Nunc plates were loaded with IFN-
γ capture antibody (Pierce Endogen). For detection, 50μl/well of interferon-γ 
biotinylated Mab (Pierce Endogen) was used at a concentration of 1.5 μg/ml. 
Standard preparations of recombinant human interferon gamma were prepared with 2-
fold dilutions from 2000pg/ml to 31.25pg/ml. All assays were performed in triplicate 
and PBL from lab donors acted as controls.  
Analysis: All 96-well plates analysed on the same VICTOR 
X plate reader (PerkinElmer, Cambridge) and the light absorbance was read at 
450nm. 
 
First, we evaluated the optimal method of stimulating PBL by comparing PHA, OKT3, 
and plate bound CD3/CD28 on interferon- production.  Phytohaemaglutinin (PHA) 
stimulates T-cells by binding to cell membrane glycoproteins. Plate bound anti-CD3 and 
anti CD28 monoclonal antibodies are naturally occurring proteins that stimulate the T-cell 
receptor, and using this method probably most closely reflects what happens in 
136 
 
physiological TCR activation. OKT3 is synthetic anti-CD3 monoclonal antibody in 
suspension. This preliminary series of experiments was performed using PBL to begin 
validating these studies.  PBL are not identical to TIL, but they are an appropriate starting 
point given that TIL are in scarce supply. 
 
Cells were suspended at a concentration of 5x105 cells/ml and 200l added per well.  Cells 
were then stimulated.  In order to investigate the optimal length of stimulation, the 
supernatant was harvested after 8, 23 or 47 hours incubation at 37oC/%5CO2.  ELISA was 
performed to assess interferon- production. 
 
We found that when stimulating 1x105 PBL per well with plate bound CD3/CD28 a 
maximal response in IFN- production is achieved after a short incubation of 14 hours.  
The maximal OKT3 and PHA response was seen after the longer incubation of 34 hours. 
Stimulation with PHA produced a lesser response than CD3/CD28 and OKT3 (Fig. 5.2).   
 
Using plate bound CD3/CD28 a good response could also be seen when 3x105 cells per 
well were used.  A small response could even be detected when using CD3/CD28 to 
stimulate 1x104 cells per well.  Using smaller numbers of cells per well, an early response 
was not detected at all when OKT3 or PHA were used to stimulate lymphocytes and 
supernatant was harvested after only 14 hours, and by 34 hours of incubation the response 
was still minimal.  In conclusion, plate bound CD3/CD28 MAb elicited the most dramatic 
IFN- release. 
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5.1.2 ELISA using TIL 
 
Having performed studies to measure IFN-γ production from stimulated PBL, we now 
performed selected experiments with TIL.  This involved extracting TIL by mechanical 
disaggregation and PBL by ficoll separation of peripheral blood from the same patient, 
counting cells with a haemocytometer and light microscope, and then stimulating the 
resultant cell culture.  On the basis of the previous results we rejected the use of PHA, and 
we stimulated PBL, mesenteric LNL and TIL with CD3/CD28 or OKT3 with and without 
additional IL-2. 
 
 
A well-established protocol devised within the Institute for Cancer Studies for measuring 
IFN- production from PBL was employed.  The results of this preliminary experiment to 
assess eliciting a response from TIL are seen in Fig.5.3.  It was possible to detect 
production of IFN- by TIL. The amount of IFN- produced by TIL was lower than PBL.  
Possible hypotheses for this finding are that (1) TIL are relatively anergic compared to 
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PBL or (2) that the numbers of PBL and TIL used in the assays were not equal.  This 
finding led us to take measures to validate the estimation of cell numbers to determine 
whether the decrease in IFN- production was due to a diminished ability by poorly 
responsive cells, or due to inaccurate numbers of cells in the culture wells after counting 
with the haemocytometer.   
 
5.1.3 Validation of tissue harvesting and estimation of cell numbers 
 
The following sets of experiments were designed to standardise the number of cells used 
in the assay.  Initial estimation of cell numbers was obtained using a haemocytometer and 
light microscope.  Cells were re-suspended to a final concentration of 5x105 cells / ml, so, 
in a 20μl volume the aim would be for 1x104 cells.  To assess whether this method of 
counting cells was accurate we used flow cytometry to count the number of isotype, CD3+ 
and CD4+ cells in a sample size of 20μl.  A ‘volume stop’ program was set up on the 
Coulter Epics XL-MCL flow cytometer.  This involves the cytometer drawing up precisely 
20l of suspension, and an assessment of the exact number of cells passing through is 
obtained.   Fig. 5.4 shows the average number of cells lying in the gated area after flow 
cytometric counting of cells using a volume stop protocol in thirteen different patients. 
Shown is the average of three readings from each tissue sample.  In one patient no PBL 
were present on flow cytometry.  The ratio of the median number of TIL: PBL was 0.42. 
Regarding the flow cytometry scatter plot, the median number of cells in the putative TIL 
population (gate R1) was 2493 (interquartile range 827 – 4920).  The median number of 
PBL in R1 was 6000 (interquartile range 3128 – 7809).   The ratio of median LNL: PBL 
was 0.74. 
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Fig. 5.5 shows the actual number of CD3+cells per well that were obtained when aiming 
for 1 x104 lymphocytes, with the cell counts being determined using a flow cytometry 
protocol. When PBL, LNL and TIL are counted by light microscope, there is a large 
degree of variability in the number of CD3+ cells obtained.  The number of PBL versus 
TIL was significantly different (p=0.0004 using Mann Whitney Test).  Whereas there was 
not much difference between PBL and LNL (p=0.7662 using Mann Whitney test).  The 
conclusion from this finding is that when using functional assays to compare PBL versus 
TIL, you either have to compensate by adding more TIL (which is unlikely to be possible 
given the amount of tissue obtained), or have a range of dilutions of PBL so that it is 
possible to make a more accurate comparison with TIL once the true CD3 numbers put 
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into the assay are known (which can only be performed retrospectively as fresh TIL need 
to be used for the functional assay before flow cytometry can be undertaken).  In some 
patients, in whom there was virtually no detectable TIL on flow cytometry, further 
functional studies could not be undertaken, again highlighting that the addition of a flow 
cytometry step to validate the number of cells present is essential when undertaking 
ELISA for measuring cytokine production from TIL. 
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5.1.4 ELISA to assess IFN- production from TIL 
 
Aim: Measurement of IFN-gamma production from stimulated PBL, TIL and LNL 
Patients : 
Paired PBL LNL and TIL n=8 (patients 5,6,8,11,12,16,15,18) 
Assay: ELISA IFN-gamma (section 2.2.5) 96 well Nunc plates were loaded with IFN-
γ capture antibody (Pierce Endogen). For detection, 50μl/well of interferon-γ 
biotinylated Mab (Pierce Endogen) was used at a concentration of 1.5 μg/ml. 
Standard preparations of recombinant human interferon gamma were prepared with 2-
fold dilutions from 2000pg/ml to 31.25pg/ml. All assays were performed in triplicate 
and PBL from lab donors acted as controls. 
Analysis: All 96-well plates analysed on the same VICTOR 
X plate reader (PerkinElmer, Cambridge) and the light absorbance was read at 
450nm. 
 
The objective of this series of experiments was to see if there is functional impairment of 
TIL versus PBL from the same patient.  Using the optimal methods of TIL stimulation 
previously described, IFN- release was measured after stimulation of lymphocytes 
obtained from eight consecutive patients undergoing surgery for colorectal cancer.   
 
IFN- production was seen from TIL from five out of eight patients and in three patients 
no or very little response could be detected.  In the other five patients much less IFN- was 
produced by TIL than by PBL.  In the three patients who had no detectable production of 
IFN-, only one had a convincing lymphocyte population on the flow cytometry used to 
validate the experiments, again highlighting the need for validation of the TIL population 
if these methods are to be used in assessing the response after future neo-adjuvant trials.  
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In contrast, there was one patient with very low numbers of TIL who had some detectable 
cytokine release.   
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If we assume a linear relationship between PBL versus IFN-γ, then we were able to predict 
what the response from an equivalent number of PBL and TIL in each paired sample 
would be (fig. 5.6).  In all cases but one, there was still a decrease in the amount of IFN-
gamma produced indicating some degree of anergy of TIL compared to PBMC.  These 
results are hypothesis generating as the samples sizes are small to make definite 
conclusions, but the results do suggest a variability in the functional competence of TIL.  
By calibrating for cell numbers the reduction in cytokine release from TIL is less than 
previously thought.   
 
After analysing the results of the assays from these eight patients, it became clear that in 
order to calibrate the number of PBL in suspension with the number of TIL in suspension, 
a range of concentrations of PBL could be included, for example 1x105, 3x104 and 1x104 
cells per well.  Therefore, if there subsequently turned out to be fewer TIL than expected 
used for the experiment, we would have a comparative response of cytokine production 
from PBL to use for evaluation.  Figure 5.7 shows the results obtained from PBL, LNL 
and TIL from one patient, comparing the exact number of CD3+ cells (measured by flow 
cytometry) versus the amount of interferon gamma produced. A regression line drawn 
through the results from different concentrations of PBL allows us to conclude that TIL 
produced less IFN-gamma than PBL.  We can make this assumption since the number of 
TIL fall in the middle of the regression line.  It would be wrong to extrapolate the line, and 
as such we cannot make a comparison with the amount of IFN-gamma produced by LNL. 
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A correlation between cell numbers counted by flow cytometry and IFN- production can 
be seen in the graph in Figure 5.8.  This shows that after validating the cell numbers, there 
is still a large degree of variability. It will not just be the number of cells present that 
influence the amount of cytokine produced, and other factors, perhaps the presence of 
regulatory T-cells, may have an effect.  A Runs test was performed which determines 
whether the two elements, number of TIL and IFN-γ production, are mutually 
independent.  The result, r2 was 0.53, indicating that 50% of the variability was not due to 
the number of cells present. 
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5.1.5 Magnetic Cell Sorting 
 
In order to investigate whether cell surface receptor profiles associate with functional 
differences, the next stage was to undertake a series of experiments that involved assessing 
methods of separation of the CD4 sub-population.  For this, I first embarked a method that 
would allow CD25 depletion.  
 
Aim: Separation of CD4+CD25+ and CD4+CD25- PBL and TIL, followed by cell 
stimulation and measurement of IFN-gamma production. 
Patients: PBL from lab donor for initial assay. Paired samples of PBL and TIL: n=6 
(see table 3.1). 
Dropout rate n=3; In one there was not enough TIL for depletion studies, in one the 
tumour was too small and only PBL were harvested, and in one the culture became 
infected. 
Assays:  MACS separation using CD25 microbeads (Miltenyi biotech) and MACS 
LD column (Miltenyi Biotech) in a magnetic field.  (section 2.2.11). 
ELISA IFN-gamma (section 2.2.5) IFN-γ capture antibody (Pierce Endogen), and 
detection interferon-γ biotinylated Mab (Pierce Endogen).  Standard preparations of 
recombinant human interferon gamma were prepared with 2-fold dilutions from 
2000pg/ml to 31.25pg/ml. All assays were performed in triplicate. 
Analysis: All 96-well ELISA plates analysed on the same VICTOR 
X plate reader (PerkinElmer, Cambridge) and the light absorbance was read at 
450nm. 
 
A small series of experiments were performed using magnetic cell sorting (MACS).  The 
effect of MACS to separate putative T-regulatory from effector T-cells was assessed by 
depletion of CD4+CD25+ cells.  Peripheral blood was obtained from a lab donor and 
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lymphocytes separated by Ficoll gradient.  The MACS protocol as described in section 
2.2.11 was followed.  Flow cytometry was performed to confirm depletion of CD25+ 
cells. This confirmed that following separation the negative fraction was free of CD25+ 
cells (Fig. 5.9).   
 
 
149 
 
Following this, six patients were recruited.  Of these, only three sets of samples were 
obtained for analysis. Samples were taken pre- and post-separation to be used for flow 
cytometric analysis.  Separation of samples of TIL can be seen in Figure 5.10.   
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The remainder were stimulated with plate bound CD3 and CD28, and subsequent IFN- 
release from the pre-separation sample versus the post-separation negative fraction 
measured using ELISA.  The results were interesting, as in some samples depletion of 
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CD25+ cells increased IFN- release, whereas in others release was inhibited (Fig. 5.11).  
In removing both CD25high cells and CD25low cells, we may have been diminishing the 
number of active, IFN-gamma producing CD25low cells.  It was clear that this was an area 
that needed technological development so we did not persist with this line of investigation.  
More recently, new methods for isolating TREG with MACS beads have been developed 
using selection of CD25+ cells combined with depletion of CD127, which is present on 
activated T-cells but absent on TREG.  This was not available at the time of study. 
 
 
5.1.6 Flow assisted Cell Sorting 
 
Flow Assisted Cell Sorting (FACS) is a specialized method of flow cytometry that 
separates cells depending on the scatter and fluorescence properties of cells (fig. 5.12).  It 
separates cells bound to a fluorochrome, which in turn is conjugated to the cell surface 
marker of interest.  For this method, the gates are set on a forward versus side scatter plot, 
and only the cells that fall in this area will be collected into test-tubes. It allows very 
accurate separation of populations of cells.   
 
FACS sorting of CD4+CD25+ cells would be possible, but at this stage we chose to 
investigate CD4+CXCR6+ both out of interest and because the separated subgroups would 
be more equal in size, which would be a benefit for the subsequent functional analysis.   
 
Aim: Separation of CD4+CXCR6+ and CD4+CXCR6- TIL, followed by cell 
stimulation and measurement of IFN-gamma production. 
Patients: 
TIL: n=4 (table 3.1) 
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Assay: Flow assisted cell sorting (section 2.2.14).  TIL stained with mouse anti-
human CXCR6 clone 56811.111 (R&D systems UK), mouse antihuman-CD3 (PC5) 
and mouse antihuman CD4 (PE) (Coulter, UK).  Isotype control used.   
CD4+CXCR6+ and CD4+CXCR6- TIL populations were obtained.  Samples were 
split to those which were stimulated by plate bound CD3/CD28 MAb and those left 
un-stimulated.  ELISA IFN-gamma (section 2.2.5) was performed using IFN-γ 
capture antibody (Pierce Endogen), and detection interferon-γ biotinylated Mab 
(Pierce Endogen).  Standard preparations of recombinant human interferon gamma 
were prepared with 2-fold dilutions from 2000pg/ml to 31.25pg/ml. All assays were 
performed in triplicate.  Analysis was performed using the VICTOR X plate reader at 
light absorbance of 450nm. 
 
FACS separation of CXCR6+ cells was undertaken in five patients.  A typical plot 
showing the regions of CD4+CXCR6- and CD4+CXCR6+ cells which were collected can 
be seen in Fig. 5.12.   
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In one patient not enough cells were obtained for further analysis.  In the other four 
patients there were adequate numbers of cells obtained to perform further studies.  Cells 
were stimulated with plate bound CD3/CD28 MAb and after 24 hours incubation, ELISA 
for INF- production from TIL was performed.  The results obtained from stimulation of 
TIL were very interesting and can be seen in Figure. 5.13. In three patients CD4+CXCR6+ 
cells produced significantly more IFN- than the CD4+CXCR6- subset.  These results 
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could suggest that in TIL, an active subpopulation is defined by having a CXCR6+ 
phenotype.  
 
5.1.7  ELISA to assess IL-10, TGF-β and IL-4 production 
 
Aim: Measurement of IL-10, TGF-β and IL-4 from stimulated PBL and TIL. 
Patients:  These assays were performed in parallel to those done for IFN-γ but each 
assay required modifications as sequential specimens were obtained, and in some 
cases extra assays were required in an attempt to validate the procedures. 
PBL, LNL and TIL: n=11  
IL4: initial validation using PBL from a healthy donor. 
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Assay: ELISA for IL-10 (section 2.2.8), Coating antibody (Pierce Endogen) used at a 
concentration of 2μg/ml, and detection antibody (Pierce Endogen) at 1.5μg/ml. All 
assays performed in triplicate. 
ELISA for TGF-β (section 2.2.9), performed using the Duoset development system 
(R&D systems).  An acid activation step was required to activate latent TGF-β1 using 
0.1ml 1 N HCl was added per 0.5ml sample.  Assay was adapted to use serum free 
media, AIM V (Gibco, Invitrogen Corporation).  
ELISA for interleukin-4 (section 2.2.10) was performed using the Duoset 
development system (R&D systems).  Assay was repeated in the presence of IL-4 
receptor antibody (R&D systems). All assays were performed in triplicate. 
Analysis: VICTOR X plate reader measuring absorbance of light at 450nm. 
5.1.7.1 ELISA to assess IL-10 production 
 
The panel of cytokines tested was extended to include analysis of IL-10 production.  A 
similar protocol was employed as was used for IFN- γ, but the results were not as easily 
reproducible.  We found that the absorbance of even the standard for IL-10 was very low 
compared to the colour change seen with IFN- (Fig. 5.14).  We attempted to address this 
issue by comparing different types of buffer to coat each well (Fig. 5.15), but no 
improvement in colour was achieved.  
 
PBL from eight patients produced a usually small but detectable amount of IL-10 after 
stimulation (example of one patient shown in Figure. 5.16).  TIL from four out of eight 
patients produced IL-10, but this was a smaller response than the corresponding PBL.  The 
average production from paired samples of PBL and TIL from eight patients can be seen 
in Figure 5.17. When numbers of cells were validated with flow cytometry, which again, 
uses the assumption of a linear relationship between the number of cells and amount of 
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IL10 produced, the predicted response from an equal number of TIL (compared to PBL) 
calculated, there was relatively more IL-10 produced by TIL than by corresponding PBL 
in 3 cases. 
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5.1.8 ELISA to assess IL-4 production 
 
With the IL-4 ELISA there were again difficulties in detecting a colour change with 
stimulated PBL.  It is thought that the half-life of free IL-4 in a culture of lymphocytes is 
short, as cells again take up the cytokine.  Using anti-human IL-4 receptor MAb as a 
blocking agent (RnD Systems) can prevent this and allow a colour change to be detected 
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(Fig. 5.18).  Only very low concentrations of this cytokine were detected with PBL and no 
response was detected with TIL.  
 
5.1.9 ELISA to assess TGF- production 
 
Transforming Growth Factor-β has important effects on the cell cycle of most cells, it is 
important in the differentiation of regulatory T-cells, and is also released by TREG. It is also 
present in the commonly used serums used for cell culture, such as fetal calf serum.  When 
we attempted to analyse the production of this cytokine, we found there was very high 
background levels of TGF- detected when using standard culture medium of 8% fetal 
calf serum.  We went on to compare TGF-β levels present in 2% FCS, 8% FCS and AIMV 
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(which is serum free and contains L-glutamine, streptomycin sulphate and gentamicin).  
Using AIM V did eliminate the high background levels of TGF-β (Fig. 5.19). 
 
TGF- production was then assessed after stimulation of PBL, LNL and TIL from six 
patients.  In three, there was no production detected at all.  In the other three patients, the 
general trend was that stimulation with CD3/CD28 or IL-2 did not increase the amount 
produced above background levels, but in two out of three patients, PBL tended to 
produce more than TIL overall (Fig. 5.20).  These experiments were all performed using 
AIMV as the culture medium.  
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5.1.10 ELISA versus ELISPOT 
 
Aim: Compare the sensitivity of ELISA versus ELISPOT to measure IFN-gamma 
production from PBL 
Patient: n=1 
Assay: ELISA IFN-gamma (section 2.2.5) , ELISPOT (section 2.2.6) 
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The initial reason we chose ELISA to measure cytokine response was efficiency.  With 
ELISA cells are stimulated in a routine culture dish, then after the time period of the 
culture has elapsed the dish is spun in a centrifuge so that all cells settle at the bottom and 
200 µL of supernatant can be harvested.  This can be used for up to four separate assays.  
By contrast, ELISPOT usually requires a separate aliquot of 1x105 cells to be added 
directly to the assay, for each cytokine to be tested, meaning it could be more likely that 
inadequate cell numbers are achieved to test for more than one cytokine.  As the study 
progressed, the focus for subsequent analyses was mainly on IFN- release, it became 
appropriate to consider ELISPOT (although today other methods would now also be 
considered – see below). 
  
An experiment comparing ELISA and ELISPOT for interferon- release after stimulation 
of PBL with OKT3 was performed (Fig. 5.21).  ELISPOT plates have antibody coated 
membranes, so that when cells are cultured on the membrane, any released IFN-γ will bind 
to the antibody.  CD3 and CD28 could not be used in the ELISPOT wells as they must be 
bound to the plates prior to cell culture.  Following stimulation with soluble OKT3, a 
comparison of the sensitivity of ELISA versus ELISPOT was undertaken. Figure 5.22 
shows that ELISPOT also gives an idea of how many cells are functionally active as well 
as how much IFN-γ is produced as each functionally active unit produces an individual 
spot which is then read by a plate reader.   
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Figure 5.22 shows that in this experiment, ELISPOT was superior at recognising levels of 
IFN-γ produced from lower concentrations of cells added to the assays, but this finding is 
limited by the fact it was only performed at one time-point and in samples from one 
patient. 
 
There are other methods of measuring cytokine production in routine use, such as 
multiplex cytokine array detection and intracellular cytokine staining with flow cytometric 
analysis.  At the time of study, Multiplex Cytokine Array Detection, which would have 
allowed assessment of a larger range of cytokine release from a small volume of 
supernatant, was not available to us, but should be a consideration for future trials. Using 
kit that was available to us from within the department, we attempted to measure IFN- 
release using intracellular cytokine staining with flow cytometry using activated PBL from 
two patients, but found we were unable to detect a response.   
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6 Discussion 
Many studies assessing anti-tumour responses in CRC have concentrated on CD8+ 
cytotoxic T-Lymphocytes. This study concentrates on CD4+ T-Helper cells because they 
are the predominant cell type found in colorectal cancer (7), and they have a pivotal role in 
regulating most antigen-specific immune responses.  Studies have shown that CD4+ T-
cells have a central role in modulating the anti-tumour response (69) (182), not only by 
priming naive CD8 cells but also by activating eosinophils and macrophages that produce 
superoxide and nitrous oxide to aid tumour cell destruction.  Small groups of experiments 
were performed with the aim of identifying different subgroups of CD4+ TIL present in 
CRC and to compare different methods of analysing the functional response from both the 
whole TIL population and of specific subgroups identified. 
 
6.1.1 Determination of heterogeneity of the CD4+ T-cell population in CRC 
 
Flow cytometry, flow assisted cell sorting and ELISA for interferon gamma, enabled us to 
characterise CD4+ lymphocytes in colorectal cancer to identify sub-populations of TIL 
that are capable of opposing immunological responses. One might expect that the 
proportion of suppressive T-regulatory CD4+ cells versus CD4+ cells capable of 
producing a Type 1, interferon-γ mediated anti-tumour response will in turn have 
implications on tumour progression or regression.   
 
Our data suggests that not only do certain homing markers appear to be associated with the 
selective uptake of CD4+subtypes into colorectal tumours, but in the case of CXCR6 this 
marker identifies a group of cells that are functionally active.  We have also shown the 
presence of putative T-regulatory cells by the expression of CD25HIGH (using flow 
cytometry) and Foxp3 (using immunohistochemistry). Expression of these 
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CD4CD25HIGH regulatory cells appeared higher in colorectal cancer compared to 
peripheral blood.  Although this thesis does identify some heterogenous subtypes of the 
CD4+ population, there are limitations of the work presented and these shall be discussed 
in this chapter. 
 
6.1.2  Technical considerations 
 
Throughout the study the aim was to optimise the methods of lymphocyte harvesting and 
control the quality of the assays undertaken.  A study of this type is reliant on obtaining 
adequate amounts of live lymphocytes from fresh colorectal cancer specimens.  
Harvesting of TIL can be a complicated process due to several factors including the small 
size of the biopsy, imprecise nature of using mechanical disaggregation to extract 
lymphocytes, significant contamination with other cell types and further loss of cells if 
using a ficoll gradient in an attempt to purify the sample.  In accordance with the 
pathologist’s wishes, in order to not impair histological staging and grading of the tumour, 
the size of the biopsy taken was limited to less than one fifth of the size of the tumour, and 
as this could not be calculated precisely it was likely that I erred on the side of caution in 
order to not compromise tumour staging.  This resulted in tissue specimens as small as 
0.3g in weight. All the these factors limited the work presented in this thesis as a complete 
data set for every patient could not be obtained if inadequate numbers of TIL (or LNL) 
were harvested.  Subsequently there was a high dropout rate for some experiments, for 
example, in the series of 12 patients recruited to assess homing marker expression data 
was obtained from only nine patients.  These difficulties are reflected in literature, as (1) 
studies using live TIL are sparse and those that are published tend to have high dropout 
rates and low numbers of patients and (2) previous immunotherapy trials for colorectal 
cancer have assessed immunological outcomes using PBL or antigenic skin reactions. An 
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early study describing mechanical and enzymatic disaggregation of different solid tumours 
found that between 1 × 104 to 7.6 × 106 lymphocytes per wet gram of tumour was obtained 
(183). 
 
It was found that several factors can help to maximise the number of lymphocytes 
obtained.  These included harvesting as close to 1g of tissue as possible from the rolled 
edge of the tumour, transporting the specimens in colonic antibiotic cocktail culture media 
without delay, and proceeding straight to mechanical disaggregation of tissue.  Despite 
this, the absolute cell numbers remained very variable.  It may be in part due to the degree 
of lymphocytic infiltration, which we know can vary from being low, moderate or 
pronounced (JR Jass, (5)). A pathologist’s opinion on the degree of lymphocytic 
infiltration was sought, but it was felt by the pathologist that assessing lymphocyte 
infiltration on conventional histology was observational and without rigorous scientific 
method to accurately measure lymphocytic infiltration. Histological analysis of the degree 
of lymphocyte infiltration would vary greatly depending on the area of tumour viewed 
microscopically, and therefore any assessment given would be arbitrary rather than a true 
scientific reading. When compared with the literature, the fact that low cell numbers were 
obtained in some cases is not unexpected.   
 
Mechanical disaggregation has some major pitfalls in that it is not possible to know if all 
available TIL are extracted, and there may be considerable contamination with tumour, 
epithelial, stromal, and other immune cells.  An alternative to mechanical disaggregation is 
enzymatic degradation with collagenases, but this process can alter membrane bound 
receptors.  Previous studies have shown that collagenases can reduce CD4 expression after 
only 15 minutes incubation, and there may also be implications for this happening with 
other glycoprotein receptors (170).  
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After lymphocyte suspensions were obtained flow cytometry was used to assess the CD4 
population phenotype.  The nature of flow cytometry, which involves an individual 
observer setting  gates on the scatter plot to identify the lymphocyte population (named R1 
on the scatter plots seen in chapter 4) before the number of cells that stain positively for 
the test antibody or antibodies are calculated, means that there will always be a degree of 
error.  If some TIL lie outside the region that is initially gated to be included in the 
analysis, results could be misleading. This is generally not a problem with PBL where 
distinct populations are easily seen, but the plots obtained when using a TIL suspension 
can be difficult to analyse due to contamination with dying or other cell types.  Using 
fresh, unfixed samples and performing flow cytometry on the day of specimen collection 
improves the quality of the data obtained.  In most cases it was possible to identify a viable 
CD3+/CD4+ population, but in line with the findings of other studies analysing TIL, in 
some cases it is difficult to purify the TIL suspension adequately enough to clearly 
identify a viable TIL population on flow cytometry. Inability to harvest and adequately 
identify a lymphocyte population on flow cytometry is potentially a drawback of using 
these techniques and resulted in large dropout rate, and this would have implications if 
used in future vaccine trials, as it would reduce the robustness of the study.   
 
There is a further source of observer error in analysing flow cytometry data that occurs 
during the analysis after the lymphocyte population (R1) has been identified.  This is when 
marker (M1) that measures the number of cells that exhibit fluorescence intensity above a 
certain level is set by the observer (see figure 4.13 for an example). The marker is set by 
using the population of cells that have not been stained by primary antibody.  The 
percentage of cells falling in the region of M1 that stained positively by the isotype control 
was subtracted from percentage of cells that stained positive for the primary antibody.  
The fact that there was increased uptake of isotype by both TIL and MIL compared to 
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PBL and LNL, means that there is possibly artificially lower readings for expression of 
markers by TIL and MIL (i.e. when addition of isotype to homing marker percentage 
expression would equal more than 100), but this could not be avoided. Ideally this analysis 
should be performed by more than one person in order to reduce intra-observer variation 
but this is not a control of error that I have seen mentioned in the literature probably due to 
the time consuming nature of this type of analysis.   
 
Despite these limitations of flow cytometry, I maintain that understanding interactions and 
function of lymphocytes at the tumour site is important in both understanding the 
pathological progression of CRC and the effect of any intervention undertaken to treat the 
disease, and flow cytometry with the use of live TIL is the optimal process to undertake 
this so as to prevent the loss of cell surface receptors that can be seen with techniques such 
as immunohistochemistry. 
 
6.1.3 Analysis of Regulatory T-cells Markers in CRC 
 
The work presented in this thesis is an important first step in analysing the presence of a 
regulatory subset of CD4 cells in CRC. When this study began, there were no documented 
studies in the literature confirming the presence of TREG.  There are now several studies 
that have addressed this (98) (100) (184) (185) (186), but with some conflicting results.  
The Bernt study (98), had shown a decrease in the incidence of CD25+ cells in CRC, but 
they did not concentrate on the CD25High subset, and hence may not be exclusively 
concentrating on the regulatory subset.  We have shown that when assessing only the 
CD25high proportion of CD4+CD25+ cells, there is a significantly higher incidence in 
tumour compared to matched peripheral blood, 7.9% versus 1.8 % respectively (p=0.0013 
and n=12).  To corroborate this finding of a regulatory subset, matched tumour specimens 
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from 12 patients were analysed for FOXP3 expression using immunohistochemistry. This 
confirmed that there was evidence of scattered intraepithelial TREG in every patient tested 
without exception. There are some limitations to this finding, such as a lack of assessing   
intra-observer variation, as only one pathologist analysed the slides. In addition, positive 
and negative tissue controls for Foxp3 were not used, but control sections were incubated 
without primary antibody.  A limitation of this analysis is that it does not tell us whether 
CD4CD25HIGH cells are selectively taken up into tumour or if TIL differentiate into TREG 
once in the tumour environment.  
 
The next step was to confirm whether these CD4CD25HIGH cells in CRC are associated 
with suppression of the rest of the CD4 population. MACS depletion of CD4+CD25+ cells 
was performed, and function of the stimulated negative fraction assessed with ELISA for 
IFN-γ production, but there were several flaws with this process and I did not gain 
valuable results. Crucially, there was no control over whether we depleted only 
CD25HIGH cells, which have a regulatory function, or the total CD25+ cell population, 
which will also contain functional Type 1 CD4 cells that typically display low levels of 
CD25.  To address this issue future investigation could employ the use of newer MACs 
beads for CD25 positive selection and CD127 depletion, with the aim of selecting out the 
regulatory subgroup, or FACS sorting that would allow accurate separation of exclusively 
the CD25HIGH fraction. Unfortunately there was not the opportunity or resources to 
perform this at the time of study.  
 
6.1.4 Analysis of T-cell Homing Markers in CRC 
 
The work in this thesis presents an overview of the homing marker expression of 
lymphocytes in tumour and normal mucosa of the colon.  Prior to the study it was well 
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known that CD62L (also known as L-selectin), integrin α4β7 and chemokine CCR7 have a 
role in the selective uptake across gut endothelium (133) (134) (135) (136), although these 
studies are mainly confined to homing to the small intestines Peyer’s Patches.  As 
chemokine receptors have been described as being homeostatic, inflammatory or dual 
function, the inference is that certain homing markers may be associated with a particular 
functional capability. The main reason chemokine receptor expression was investigated 
was to identify whether any of these markers could predict whether cells capable of an 
inflammatory response were present in the CRC tumour microenvironment.  The 
chemokines known to be associated with inflammation include VLA-4, CCR1, CCR2, 
CCR5, CCR6, CXCR3, and CXCR6. The whole panel of homing markers available was 
investigated, as the literature concerning chemokine receptors and the colon was sparse.  
The panel of chemokines receptor antibodies was analysed with matched PBL, TIL, MIL 
and LNL suspensions. One limitation of testing a large number of markers in a small 
number of samples means that we do increase the likelihood of witnessing a rare event and 
falsely rejecting the null hypothesis. A Bonferroni correction was performed to identify 
the appropriate level of significance. If the traditional level of significance is set at 0.05, 
the Bonferroni correction is calculated by dividing 0.05 by the number of comparisons 
taking place, which in this case equalled 54. Therefore, for a result to be considered to be 
significant, p should be less than 0.0009.  However, it must also be considered that 
accepting this as the level of significance could mask interesting trends. It would be better 
to perform further studies in order to reach significance. 
 
When comparing blood and tumour lymphocytes, the most dramatic increase in 
chemokine receptor expression was seen with CXCR6, which is associated with a Type-1 
T-cell response (127), and the differences did reach significance when applying the 
Bonferroni correction.  These findings represent the identification of a sub-population 
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within CRC that had not been previously identified within this disease, and may contribute 
to anti-tumour responses. The expression of CXCR6 on normal mucosal epithelial cells 
has been previously documented by a study that used immunohistochemistry to evaluate 
expression in both CRC and normal mucosa (187), but they had found very little 
expression within CRC itself.  The reasons for the difference seen between the Wagsater 
paper and my findings include that it is possible that chemokine expression is altered by 
the fixation of tissue that was subsequently used for IHC, and this again highlights the 
need to use live TIL for this type of analysis.  Since our study was undertaken, a study 
from 2007 has shown that up-regulation of CXCL16, the ligand for CXCR6, is seen in 
CRC, and that those tumours with higher levels of CXCL16 had higher levels of CD4 and 
CD8 TIL on immunohistochemistry (188). They did not examine CXCR6 expression on 
TIL, but they did measure CXCR6 RNA in tumour tissue and found higher levels in 
tissues with increased expression of CXCL16. Higher expression of CXCL16 was 
associated with a better prognosis.  This study corroborates our findings that CXCR6 
expression on TIL is a significant finding. 
 
Flow assisted cell sorting of CD4+CXCR6+ cells, followed by functional analysis 
revealed exciting results.  Flow assisted cell sorting is the most accurate method of sorting 
cells into subgroups based on cell surface markers, working with single cell resolution and 
resulting in extremely high levels of purity. It is however technically demanding, time 
consuming and expensive. Cells were sorted into a CD4+CXCR6+ population and 
CD4+CXCR6- population.  Exact numbers of cells obtained were also known from the 
cytometer reading, so it was known very accurately how many cells were subsequently 
stimulated and cultured before harvesting the supernatant and performing ELISA for IFN-
γ.  There was increased production of INF- from CXCR6+ TIL in the four patients in 
whom there were enough cells obtained to perform functional studies.  This finding does 
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of course have many limitations, most importantly the small sample size.  As such it was 
not appropriate to perform statistical analysis and the results from this small cohort of 
patients merely generates the hypothesis that CD4+CXCR6+ TIL from CRC are capable 
of producing a Type 1 T-helper cell response when stimulated.  The other limitations 
include (1) there are patients in whom not enough lymphocytes can be harvested for this 
type of study (this included 2 of 6 patients in this study),and this could lead to a sample 
error as we are automatically excluding some patients, (2) systematic errors such as the 
calibration of the FACS machine (minimised by the fact that this was supervised by an 
expert technician and the same machine was used for all analyses) and (3) Observer errors 
associated with flow cytometry analysis as previously mentioned (such as the setting of 
gates on the scatter plot that could inadvertently exclude part of the lymphocyte 
population). Despite this, these results do suggest that enhancing the CD4+CXCR6+ 
population in TIL could be beneficial but, these studies need to be repeated in a larger 
number of patients to confirm that CXCR6+ TIL are effectors of the IFN-γ response and 
also to determine if their presence correlates with better prognosis.  Only then would it be 
reasonable to suggest that CXCR6 expression alone could be used as a biomarker of a 
positive anti-tumour response. 
 
Other homing markers, such as CCR5, CCR6, PSGL1 and VLA-4, revealed a trend 
towards higher levels of expressed by TIL, but, small patient numbers meant that these 
changes were not statistically significant and could be random events.  CCR5, CCR6, 
PSGL1 and VLA-4 are all known to contribute to homing of T-cells with TH1 capabilities 
(173) (175).  There was a high level of VLA-4 expression, and moderate level of PSGL1 
expression by TIL.  Although these results are not statistically significant it is important 
that we do not exclude them entirely, as colorectal cancer is diverse, and it may be that in 
the future a panel of various different immunological markers assessed by a cluster 
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database could be used to predict tumour prognosis or response to treatment. This study is 
a first step in attempting to identify potential markers of interest.  
 
6.1.5 Methods of Measuring the Functional Response of the Total TIL Population 
 
Functional studies using live colorectal TIL are sparse in the literature probably due to the 
fact the process of obtaining a decent yield of cells can be difficult. A study from 2006 
(189) in which sentinel node and tumour lymphocytes from 15 patients were obtained at 
the time of surgery, and then assessed using flow cytometry for CD4, CD8 and CD69 (for 
early T-cell activation) found no response from TIL in proliferation assay.  They also 
assessed TIL function by IFN-gamma ELISA after stimulation in six patients. They 
identified IFN-gamma production in only one patient; in two patients there was no 
evidence of release and in three patients they did not obtain enough TIL to proceed with 
the assay.  In this study, there is assessment of various methods of analysing the function 
of TIL, including assessment of cell stimulation techniques, ELISA for a panel of four 
cytokines, and ELISPOT for IFN-γ release. 
 
In order to achieve good quality control for functional assays calibration of cell numbers is 
essential.  A method of validating the number of cells has been described using a ‘volume 
stop’ protocol with the flow cytometer.  As TIL produce relatively low levels of IFN- it 
was important to discover which method of cell stimulation produced a maximal response.  
We found this to be CD3/CD38 monoclonal antibodies (which act directly to activate the 
T-cell Receptor), with the addition of the pro-inflammatory cytokine IL-2.  This method 
also resembles most closely what happens in vivo, and consequently we used this for all 
further functional analyses.  In future vaccine trials, it may also be appropriate to measure 
responses to the tumour associated antigens that the vaccine is targeting, although by 
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doing so there may be exclusion of TIL that are responding to a different antigenic 
epitope. The timing of removing supernatant for analysis does seem to be of importance.  
We found that a maximal IFN- response was produced around 24 hours after cells had 
been stimulated, but may begin to decrease by 48 hours after stimulation.   
 
I found that TIL produce less IFN-γ than PBL. The amount of cytokine produced by TIL 
could in part be explained by the number of cells actually counted into the assay, but some 
of the variability must be due to other factors promoting anergy. The advantages of using 
IFN-γ ELISA are that there was good sensitivity, and the studies using PBL show that it is 
reproducible and robust. All assays performed in this study were performed in triplicate 
and narrow error bars were achieved.  The fact that a quantitative result regarding the 
amount of IFN-γ produced is also a benefit.  There are of course limitations to using this 
procedure, again, with the issues of purifying TIL samples and obtaining adequate 
numbers of TIL.  We measured the actual number of cells that were added to each ELISA 
well by using a ‘volume stop’ protocol on flow cytometry which should be more accurate 
than light microscopy as every single cell is counted in a 20µl sample by the cytometer, 
rather than an observer counting a vastly smaller number of cells by eye.  This could only 
be performed after lymphocytes had been put into the ELISA, so it could only be used to 
calibrate results at the end of the assay.  Setting a concentration gradient of PBL makes it 
easier to compare ELISA results obtained from TIL and PBL, as calibrating results 
depends on there being a linear relationship between the number of cells and the amount 
of cytokine produced.  Taking these limitations into account, the results suggest that in 7 
of 8 patients, TIL produced less IFN-γ than PBL. As live TIL were used (we did not have 
a bank of cryopreserved TIL that could be utilised), it meant that only one assay (of paired 
samples) could be performed at one time-point, and this means that there could be 
systematic error due to calibration of the plate reader.  The same plate reader plus a 
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standard dilution of IFN-γ was used for every assay to allow calibration of results. The 
limitations of the results again include the small sample size, but small groups of 
experiments were undertaken so that several hypotheses could be tested.  To achieve this 
we had to avoid spending too many resources (specimens and time) on each type of assay. 
 
The initial aim was to perform both a phenotypic analysis and a functional analysis on 
each set of samples. We attempted to test the production of four different cytokines IFN-γ, 
TGF-β, IL-10 and IL-4, but ELISA for the cytokines other than IFN-γ was not as robust.  
As the study progressed, experiments aiming to optimise ELISA for the remaining three 
cytokines were performed.   
 
We measured the production of IL-10 as this cytokine is produced by regulatory T-cells 
(and T-Helper type 2 cells). ELISA for IL-10 produced much lower levels of colour 
change than IFN-γ (even for the IL-10 standard preparation that was used to calibrate 
results).  Samples from eight patients were used to assess IL-10 production, and TIL from 
four produced a detectable amount of IL-10, but again the amount of IL-10 produced was 
less than PBL. Calibrating the results (given the information regarding the numbers of 
cells actually present on volume stop studies with flow cytometry), TIL seemed to produce 
more IL-10 than PBL in three of these four patients.   As the sample size is so small and 
we are manipulating the data, this result must be considered with caution, but it does raise 
the hypothesis that TIL may produce more IL-10 than PBL, and further studies with a 
larger numbers of cells and larger sample size are indicated given the suppressive nature 
of this cytokine. 
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The sensitivity of TGF- ELISA was improved using culture medium that did not contain 
calf serum but detection was only achieved in half of the patients analysed and the amount 
produced did not respond to sell stimulation techniques. 
 
IL-4 is a cytokine associated with a type 2 T-Helper cell response.  There was initially no 
detectable response from PBL or TIL.  Previous studies suggested that this happens 
because IL-4 is readily taken up again by cells after it has been released.  The inclusion of 
a blocking agent to prevent re-uptake of IL-4 by cells in culture revealed a tiny response 
that could only be elicited with stimulated PBL. 
 
In our comparison using PBL and TIL, ELISPOT was actually more accurate in detecting 
low levels of IFN- release.  We used ELISA initially because we wanted to measure a 
range of cytokines.  With ELISA the supernatant from each well could be used for all four 
cytokine assays, whereas, for ELISPOT you would require four times the number of cells, 
a requirement which would not be possible with the cell numbers we were achieving.  
Luminex could be an excellent alternative to measure a range of cytokines, but was not 
available to us at the time of study.  Luminex is based on the principles of flow cytometry, 
but it allows you to simultaneously measure theoretically up to 100 analytes (including 
cytokine profiling) in a single well.  Studies in the literature have described the 
simultaneous detection of up to fifteen different human cytokines (190).  A study 
comparing the ability of ELISA versus Luminex to assess the production of ten different 
cytokines, in 96 patients, found excellent correlation between these two methods (191).  In 
future trials, this would likely be the preferential method for analysing cytokine release 
after stimulation of TIL, if available. 
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6.1.6 Clinical applications of this research 
 
The quest for new immuno-therapeutics that will enhance current treatment and promote a 
survival benefit in patients presenting with colorectal cancer is of great relevance today.  
‘Window trials’ that are undertaken in the period between diagnosis and surgery are 
currently having new-found appeal. They may provide rapid systemic treatment to target 
micro-metastases present at the time of diagnosis, with perhaps minimal delay to the 
timing of operation. Currently, with the exception of long course chemo-radiotherapy for 
rectal cancer, micro-metastases present at diagnosis are not targeted for some time, with 
the need to wait several weeks to allow healing after surgery before conventional 
chemotherapy can be commenced.   
 
Most Phase II trials are performed in patients with metastatic disease who have already 
failed other forms of treatment.  These patients generally have a high burden of resistant 
disease that may not show response to immunotherapy.  Window trials, in which the 
therapy is given to patients who are at risk of treatment failure (e.g. tumours identified as 
locally advanced on CT scan), receive the novel intervention prior to standard therapy.  
The target population will therefore include patients who are at risk of recurrence, but who 
have a lower burden of disease, that may proceed to show a complete response.  Several 
window studies for treatment of other tumours have been published recently (192) (193) 
(194) (195). One study, in which patients with early stage breast cancer, were given 
fluvastatin pre-operatively, had shown by analysing the resected specimen that the 
proliferation rate of high grade tumours was decreased, and apoptosis of tumour cells was 
increased (194).  Another window trial published in 2006 assessed the effect of COX-2 
inhibitors when used for 14 days prior to surgery for nasopharyngeal carcinoma (195). 
They found that tumour angiogenesis was decreased and there were changes in gene 
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expression including transcription factors and cell signalling molecules.  Studies like these 
can allow generation of hypotheses to target new areas of investigation. 
 
A schematic representation of the processes involved in a window trial can be seen in 
figure 6.1. When a patient receives any type of pre-operative treatment, whether a vaccine, 
molecularly targeted agent or conventional chemotherapy, there is the opportunity of 
surgery to harvest tumour and study the TIL population present.   
 
 
All forms of anti-cancer treatment may alter the immune microenvironment.  For example, 
the conventional chemotherapy agent cyclophosphamide has been shown to reduce the 
presence of TREGs in the pancreas (196).  Understanding how the immune response is 
behaving following various types intervention may help improve the design of future 
trials.   
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7 Conclusion 
 
The goal of this study was to develop methods of assessing the immune response in TIL in 
such a way that they may be used to measure immunological end-points for future window 
trials.  A secondary aim was to identify novel sub-populations of cells within CD4+ TIL in 
terms of their cell surface markers, and to determine the functional ability of these sub-
populations. 
 
The steps that we took to achieve these goals included validation of tissue harvesting 
methods, flow cytometry to assess a large panel of cell surface markers, and validation 
that assays such as ELISA can be  used with TIL as they can with PBMC, to measure 
function by assessing cytokine release.   We then investigated methods of separating sub-
populations of CD4+ TIL by using MACS separation techniques and flow assisted cell 
sorting, and proceeded to measure the function of these sub-populations, again by using 
ELISA. 
 
A main finding of this study is that distinct sub-populations of CD4+ T-cells exist in 
colorectal cancer.  We have identified a subgroup of T-cells that express CXCR6. Previous 
studies have shown these cells are involved in inflammatory responses. We were able to 
successfully separate the CD4+CXCR6+ population from the CD4+CXCR6- population 
using FACS.  We have shown that this sub-population of cells from CRC does indeed 
produce IFN-γ when stimulated with CD3/CD28 MAb.  This gives promise that the 
immune system could be encouraged to produce and enhanced anti-tumour response, and 
these methods could be used to assess responses after future vaccine trials.  There are 
several other homing markers that are also of interest, including CCR5, CCR6, PSGL1 
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and VLA4 and more work is required to determine whether they are up-regulated in CRC 
and what their functional significance is. 
 
We have also established the presence of CD4+CD25+High TREG, that are known to be 
involved in immune tolerance and inhibition of inflammatory responses, although since 
this study was undertaken other groups have also confirmed these findings.  We found that 
MACS separation using CD25 beads was not an appropriate method for undertaking 
functional studies aiming for CD25HIGH depletion.  Further studies to separate regulatory 
versus effector CD4 TIL, with FACS or alternative types of MACs beads are indicated. 
 
Recommendations based on this study are that immunological biomarkers can be assessed 
following phase II window trials for colorectal cancer to look for both inflammatory and 
inhibitory sub-groups of cells.  Quality control methods must be taken to optimise tissue 
harvesting and assay methods.  To measure function, ELISA or ELISPOT for IFN-γ 
release may be used, but if available LUMINEX may be more appropriate so that a larger 
panel of cytokines can be investigated.  Flow assisted cell sorting is successful for 
separating subpopulations of interest, so that function of these populations can be 
determined.  Measuring the immune response in this way will not only provide end-points 
that assess the immune response, but will provide proof of concept of the vaccines 
mechanism of action, and most likely generate further hypotheses for future areas of 
investigation. 
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8 Appendix 
8.1 Biomarker roadmap 
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